Methods and Compositions Involving Biodegradable Cyanoacrylates - Patent application
Biodegradable cyanoacrylate compositions with a cyanoacrylate, stabilizer, and polymerization inhibitor components address the issue of brittle polymers in existing cyanoacrylates by providing sustained occlusion and adhesion in biological tissues through controlled degradation and tissue response.
Patent Information
- Application Number
- JP2023187621
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-02-09
- Filing Date
- 2023-11-01
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2038-02-08
AI Technical Summary
Existing cyanoacrylate compositions used in medical and veterinary applications lack long-term integrity due to cracking and form brittle polymers, posing challenges in maintaining occlusion and adhesion in biological tissues.
Development of biodegradable cyanoacrylate compositions comprising a cyanoacrylate component, a stabilizer component, and a polymerization inhibitor component, which are formulated to polymerize in the body, maintain occlusion, and degrade over time, promoting tissue ingrowth and scarring for sustained conduit closure.
The compositions provide effective and sustained occlusion of conduits such as blood vessels and ducts by forming a biodegradable polymer that gradually degrades, inducing tissue response and scarring without harmful by-products, while maintaining adhesion and flexibility.
Smart Images

Figure 0007594647000001 
Figure 0007594647000002 
Figure 0007594647000003
Abstract
Description
[Technical field]
[0001] Related Applications
[0002] This application is a continuation of U.S. Provisional Patent Application No. 62 / 456,916, filed February 9, 2017. Priority and benefit of the filing date is claimed, which is incorporated herein in its entirety.
[0003] Technical Field
[0004] The present disclosure relates to methods and compositions comprising cyanoacrylates for medical and veterinary use. Related to the composition. [Background technology]
[0005] Background technology
[0006] In medicine and research, cyanoacrylates have been used as tissue adhesives. Cyanoacrylates known in the art generally have low viscosity for their intended use. and may contain additives. Cyanoacrylates are represented by the following formula: [ka]
[0007]
[0023] where R is an alkyl group or other suitable substituent that forms the ester portion of the molecule. Such cyanoacrylates can be represented by the formula: No. 7,224, No. 3,591,676, No. 3,667,472, No. 3,995 ,641, 4,035,334 and 4,650,826. It is well known in the art to prepare such compounds. When used in living tissue, the R substituents are most often lower alkyl (i.e. , C 1 From C 8 ) and the corresponding alkyl cyanoacrylate esters are liquid at room temperature. Lower alkyl cyanoacrylate esters are prone to cracking and therefore lack long-term integrity. It is well known that such polymers tend to form brittle polymers.
[0008] Common cyanoacrylate compositions are used in surgical sutures and staplers for wound closure. As an adjunct to needles, as well as for lacerations, abrasions, burns, stomatitis, bedsores and other superficial wounds These topical applications include those for use in covering and protecting superficial wounds such as those described above. Medical applications of cyanoacrylates include inhibiting blister formation while minimizing histological responses. It is required to form a polymer layer to provide a protective barrier to the skin. The most commonly used topical cyanoacrylate compositions have been shown to minimize histological responses while The octyl, butyl or tert-butyl ethers that incorporate low levels of sulfur dioxide are used so as not to inhibit the polymerization rate. The composition is made of a blend. Despite compatibility issues with the components and weakening of the adhesive properties of the composition, To increase flexibility, other ingredients such as plasticizers are added to the composition.
[0009] What is needed is a composition that will initiate a tissue reaction and cause an occlusion to form within the duct. Summary of the Invention
[0010] Summary of the Invention
[0011] The present disclosure provides at least one cyanoacrylate for medical and veterinary uses, such as for obstructing ducts. In particular, the present disclosure relates to compositions that prevent ductal occlusion in humans and other animals. The conduit may be a vessel or a duct in the body, such as a duct or blood vessel. In certain uses, the disclosed cyanoacrylate compositions may be and degrades over time while in the body, thus As the polymerized material degrades, tissue ingrowth or or scarring maintains occlusion, one cyanoacrylate or two or more cyanoacrylates Includes rates.
[0012] To achieve occlusion of the duct, the compositions disclosed herein include a cyanoacrylate. In some embodiments, the composition further comprises a blend or mixture of isomers of the lysate. The biodegradable composition disclosed herein may contain large amounts of stabilizers such as sulfur dioxide. The composition produces the desired reaction by inducing a tissue response that leads to a sustained occlusion. do. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] Detailed Description
[0014] Disclosed herein is a method for preventing the obstruction of a duct in a subject, such as a human or animal. 2. A method for treating a cyanoacrylate-containing medicament comprising administering to a patient a therapeutically effective amount of a cyanoacrylate, comprising administering to a patient a therapeutically effective amount of a cyanoacrylate-containing medicament, and a biodegradable composition.
[0015] Disclosed herein is a composition that comprises three components; 1) a cyanoacrylate component; and 2) a stabilizer component; and 3) a polymerization inhibitor component. In some embodiments, the composition comprises: a) at least about 80 wt. The cyanoacrylate component above and b) a stable concentration of from about 500 ppm to about 1,500 ppm. and c) about 4,000 ppm to about 7,000 ppm of a polymerization inhibitor component. wherein the cyanoacrylate component may comprise one or more cyanoacrylates. Such biodegradable cyanoacrylate compositions may be sterile compositions. The compositions disclosed herein can be formulated as liquid compositions. After the liquid composition is provided to the target site, polymerization occurs in the liquid composition, forming a polymer in the liquid formulation. It is understood that the solid material formed is the result of the reaction of the components in the disclosed The compositions used are biodegradable (also known as absorbable or resorbable compositions) and therefore do not require any solids. The body material is converted over time into its breakdown products. When agents are intended, when polymerized materials are intended, and when degradation products are intended The cases illustrated will be clear to those skilled in the art.
[0016] Disclosed herein is a composition that comprises three components; 1) a cyanoacrylate component; and A biodegradable cyanoacrylate essentially consisting of 2) a stabilizer component and 3) a polymerization inhibitor component. In some embodiments, the composition comprises: a) about 90 weight percent or more cyano. b) from about 500 ppm to about 1,500 ppm of a stabilizer component; c) essentially free of about 4,000 ppm to about 7,000 ppm of polymerization inhibitor components wherein the cyanoacrylate component comprises one or more cyanoacrylates. Such biodegradable cyanoacrylate compositions may be sterile compositions. .
[0017] In some embodiments, the biodegradable cyanoacrylate composition comprises: a) about 80.0 wt. %, 8 0.5wt%, 81wt%, 81.5wt%, 82wt%, 82.5wt%, 83wt% , 83.5wt%, 84wt%, 84.5wt%, 86wt%, 86.5wt%, 87w t%, 87.5wt%, 88wt%, 88.5wt%, 89wt%, 89.5wt%, 9 0wt%, 90.5wt%, 91wt%, 91.5wt%, 92wt%, 92,5wt% , 93wt%, 93.5wt%, 94wt%, 94.5wt%, 96wt%, 96.5w t%, 97wt%, 97.5wt%, 98wt%, 98.5wt%, 99wt%, 99. 5wt%, 99.9wt%, or 80 to 99.9wt%, 80 to 95wt%, 8 0 to 81wt%, 80 to 82wt%, 80 to 85wt%, 84 to 86wt%, 8 5 to 87wt%, 86 to 88wt%, 87 to 89wt%, 88 to 90wt%, 9 0 to 92wt%, 91 to 93wt%, 90.5 to 92.5wt%, 91 to 93w t%, 92 to 94wt%, 93 to 95wt%, 95.5 to 97.5wt%, 94 to to 96wt%, 95 to 98wt%, 96 to 99wt%, 90 to 97wt%, 90 to % and 90 to 99.9 wt % of a cyanoacrylate component; and b) About 500ppm to about 550ppm, 500ppm to about 600ppm, about 500ppm to about 650 ppm, about 500 ppm to about 700 ppm, about 500 ppm to about 750 ppm, about 500 ppm to about 800 ppm, about 500 ppm to about 850 ppm, about 5 00ppm to about 900ppm, about 500ppm to about 950ppm, about 500ppm to to about 1000 ppm, about 500 ppm to about 1100 ppm, about 500 ppm to about 12 00ppm, about 500ppm to about 1300ppm, about 500ppm to about 1400ppm m, or about 500 ppm to about 1500 ppm of a stabilizer component, and c) about 4,000 ppm m to about 4,500 ppm, 4,000 ppm to about 5,000 ppm, about 4,000 p pm to about 5,500 ppm, about 4,000 ppm to about 6,000 ppm, about 4,00 0 ppm to about 6,500 ppm, about 4,000 ppm to about 6,500 ppm, or and about 4,000 ppm to about 7,000 ppm of a polymerization inhibitor component.
[0018] In some embodiments, the biodegradable cyanoacrylate composition comprises: a) about 80.0 wt. %, 8 0.5wt%, 81wt%, 81.5wt%, 82wt%, 82.5wt%, 83wt% , 83.5wt%, 84wt%, 84.5wt%, 86wt%, 86.5wt%, 87w t%, 87.5wt%, 88wt%, 88.5wt%, 89wt%, 89.5wt%, 9 0wt%, 90.5wt%, 91wt%, 91.5wt%, 92wt%, 92.5wt% , 93wt%, 93.5wt%, 94wt%, 94.5wt%, 96wt%, 96.5w t%, 97wt%, 97.5wt%, 98wt%, 98.5wt%, 99wt%, 99. 5wt%, 99.9wt%, or 80 to 99.9wt%, 80 to 95wt%, 8 0 to 81wt%, 80 to 82wt%, 80 to 85wt%, 84 to 86wt%, 8 5 to 87wt%, 86 to 88wt%, 87 to 89wt%, 88 to 90wt%, 9 0 to 92wt%, 91 to 93wt%, 90.5 to 92.5wt%, 91 to 93w t%, 92 to 94wt%, 93 to 95wt%, 95.5 to 97.5wt%, 94 to to 96wt%, 95 to 98wt%, 96 to 99wt%, 90 to 97wt%, 90 to % and 90 to 99.9 wt % of a cyanoacrylate component; and b) About 1400ppm to about 1500ppm, about 1300ppm to about 1500ppm, about 1 200ppm to about 1500ppm, about 1100ppm to about 1500ppm, about 100 0ppm to about 1500ppm, about 900ppm to about 1500ppm, about 800ppm from about 1500 ppm, from about 700 ppm to about 1500 ppm, or from about 600 ppm to to about 1500 ppm of the stabilizer component, and c) from about 4,000 ppm to about 4,500 ppm, 4,000ppm to about 5,000ppm, about 4,000ppm to about 5,500ppm , about 4,000ppm to about 6,000ppm, about 4,000ppm to about 6,500ppm pm, about 4,000 ppm to about 6,500 ppm, or about 4,000 ppm to about 7 ,000 ppm of a polymerization inhibitor component.
[0019] In some embodiments, the biodegradable cyanoacrylate composition comprises: a) about 80.0 wt. %, 8 0.5wt%, 81wt%, 81.5wt%, 82wt%, 82,5wt%, 83wt% , 83.5wt%, 84wt%, 84.5wt%, 86wt%, 86.5wt%, 87w t%, 87.5wt%, 88wt%, 88.5wt%, 89wt%, 89.5wt%, 9 0wt%, 90.5wt%, 91wt%, 91.5wt%, 92wt%, 92.5wt% , 93wt%, 93.5wt%, 94wt%, 94.5wt%, 96wt%, 96.5w t%, 97wt%, 97.5wt%, 98wt%, 98.5wt%, 99wt%, 99. 5wt%, or 80 to 99.5wt%, 80 to 95wt%, 80 to 81wt% , 80 to 82wt%, 80 to 85wt%, 84 to 86wt%, 85 to 87wt% , 86 to 88wt%, 87 to 89wt%, 88 to 90wt%, 90 to 92wt% , 91 to 93wt%, 90.5 to 92.5wt%, 91 to 93wt%, 92 to 9 4wt%, 93 to 95wt%, 95.5 to 97.5wt%, 94 to 96wt%, 9 5 to 98wt%, 96 to 99wt%, 90 to 97wt%, 90 to 95wt% and and b) from about 500 ppm to about 90 to about 99.9 wt % of the cyanoacrylate component. to about 550 ppm, 500 ppm to about 600 ppm, about 500 ppm to about 650 ppm m, about 500 ppm to about 700 ppm, about 500 ppm to about 750 ppm, about 500 ppm to about 800 ppm, about 500 ppm to about 850 ppm, about 500 ppm to about 900ppm, approx. 500ppm to approx. 950ppm, approx. 500ppm to approx. 1000ppm m, about 500 ppm to about 1100 ppm, about 500 ppm to about 1200 ppm, about 5 00 ppm to about 1300 ppm, about 500 ppm to about 1400 ppm, or about 50 0 ppm to about 1500 ppm of stabilizer components, and c) about 4,500 ppm to about 7,00 0 ppm, about 5,000 ppm to about 7,000 ppm, or about 6,500 ppm to and about 7,000 ppm of a polymerization inhibitor component.
[0020] In some embodiments, the biodegradable cyanoacrylate composition comprises: a) about 80.0 wt. %, 8 0.5wt%, 81wt%, 81.5wt%, 82wt%, 82.5wt%, 83wt% , 83.5wt%, 84wt%, 84.5wt%, 86wt%, 86.5wt%, 87w t%, 87.5wt%, 88wt%, 88.5wt%, 89wt%, 89.5wt%, 9 0wt%, 90.5wt%, 91wt%, 91.5wt%, 92wt%, 92.5wt% , 93wt%, 93.5wt%, 94wt%, 94.5wt%, 96wt%, 96.5w t%, 97wt%, 97.5wt%, 98wt%, 98.5wt%, 99wt%, 99. 5wt%, 99.9wt%, or 80 to 99.9wt%, 80 to 95wt%, 8 0 to 81wt%, 80 to 82wt%, 80 to 85wt%, 84 to 86wt%, 8 5 to 87wt%, 86 to 88wt%, 87 to 89wt%, 88 to 90wt%, 9 0 to 92wt%, 91 to 93wt%, 90.5 to 92.5wt%, 91 to 93w t%, 92 to 94wt%, 93 to 95wt%, 95.5 to 97.5wt%, 94 to to 96wt%, 95 to 98wt%, 96 to 99wt%, 90 to 97wt%, 90 to % and 90 to 99.9 wt % of a cyanoacrylate component; and b) About 1400ppm to about 1500ppm, about 1300ppm to about 1500ppm, about 1 200ppm to about 1500ppm, about 1100ppm to about 1500ppm, about 100 0ppm to about 1500ppm, about 900ppm to about 1500ppm, about 800ppm from about 1500 ppm, from about 700 ppm to about 1500 ppm, or from about 600 ppm to to about 1500 ppm of stabilizer components, and c) from about 4,500 ppm to about 7,000 ppm, About 5,000 ppm to about 7,000 ppm, or about 6,500 ppm to about 7,00 0 ppm of a polymerization inhibitor component.
[0021] In some embodiments, the biodegradable cyanoacrylate composition comprises: a) about 80.0 wt. %, 8 0.5wt%, 81wt%, 81.5wt%, 82wt%, 82.5wt%, 83wt% , 83.5wt%, 84wt%, 84.5wt%, 86wt%, 86.5wt%, 87w t%, 87.5wt%, 88wt%, 88.5wt%, 89wt%, 89.5wt%, 9 0wt%, 90.5wt%, 91wt%, 91.5wt%, 92wt%, 92.5wt% , 93wt%, 93.5wt%, 94wt%, 94.5wt%, 96wt%, 96.5w t%, 97wt%, 97.5wt%, 98wt%, 98.5wt%, 99wt%, 99. 5wt%, 99.9wt%, or 80 to 99.9wt%, 80 to 95wt%, 8 0 to 81wt%, 80 to 82wt%, 80 to 85wt%, 84 to 86wt%, 8 5 to 87wt%, 86 to 88wt%, 87 to 89wt%, 88 to 90wt%, 9 0 to 92wt%, 91 to 93wt%, 90.5 to 92.5wt%, 91 to 93w t%, 92 to 94wt%, 93 to 95wt%, 95.5 to 97.5wt%, 94 to to 96wt%, 95 to 98wt%, 96 to 99wt%, 90 to 97wt%, 90 to % and 90 to 99.9 wt % of a cyanoacrylate component; and b) Approximately 500ppm, 525ppm, 550ppm, 575ppm, 600ppm, 625p pm, 650ppm, 675ppm, 700ppm, 725ppm, 750ppm, 77 5ppm, 800ppm, 825ppm, 850ppm, 875ppm, 900ppm, 925ppm, 950ppm, 975ppm, 1,000ppm, 1,025ppm, 1 ,050ppm, 1,075ppm, 1,100ppm, 1,125ppm, 1,150 ppm, 1,175ppm, 1,200ppm, 1,225ppm, 1,250ppm, 1,275ppm, 1,300ppm, 1,325ppm, 1,350ppm, 1,37 5ppm, 1,400ppm, 1,425ppm, 1,450ppm, 1,475ppm , or 1,500 ppm of stabilizer components, and c) about 4,000 ppm, 4,250 ppm , 4,500ppm, 4,750ppm, 5,000ppm, 5,250ppm, 5,5 00ppm, 5,750ppm, 6,000ppm, 6,250ppm, 6,500ppm m, 6,750 ppm, or 7,000 ppm of polymerization inhibitor component. .
[0022] The disclosed biodegradable cyanoacrylate compositions are referred to herein interchangeably as These compositions are sometimes referred to as cyanoacrylate compositions or occlusive compositions.
[0023] The disclosed biodegradable cyanoacrylate compositions comprise at least these disclosed The composition may include a combination of a cyanoacrylate component, a polymerization inhibitor, and a stabilizer. These may include, but are not limited to, desirable characteristics of the cyanoacrylate composition itself, delivery of the composition, or composition. It affects the material that is formed after the compound cures (polymerizes). or different amounts of each to adjust the charge morphology for, among other purposes, the physical characteristics of the cyanoacrylate composition, including but not limited to molecular weight or viscosity; Cyanoacrylate compositions and certain additives, as well as polymers, plastics, Modify the interaction with other materials such as adhesives and metals; Modifying the cellular reaction or response; including but not limited to the rate or heat of polymerization Adjust the adhesive properties of the material; the percentage of decomposition, the rate of decomposition and the amount of formaldehyde produced during decomposition Adjust the degradation profile of the resulting composition, including the components; bond strength, flexibility, grain size, Modify the physical properties of the applied cured composition, including but not limited to its hardness and adhesion. To achieve this, biodegradable cyanoacrylate compositions may be included.
[0024] In some embodiments, the biodegradable cyanoacrylate component comprises one or more types of cyanoacrylate. Acrylate monomers, such as those having the general formula: [ka]
[0025] [In the formula, R 1 is a hydrocarbyl or substituted hydrocarbyl group. Monomeric esters of 2-cyanoacrylic acid, formula: [ka]
[0026] [In the formula, R 2 is a 1,2-alkylene group having 2 to 4 carbon atoms, R 3 is 2 is an alkylene group having up to 12 carbon atoms; R 4 has 1 to 6 carbon atoms is an alkyl group. a group having the formula Or, the expression: [ka]
[0027] [In the formula, R 5 is the formula [ka]
[0028] or -[C(CH 3 ) 2 ]n-, where n is 1, 2, 3, 4, 5, 6, 7, is an integer having a value of 8, 9, 10, 11, 12, 13, or 14, and R 6 is the organic part be] The formula includes groups having the formula:
[0029] In various embodiments, the hydrocarbyl and substituted hydrocarbyl groups are 1 to 16 carbon atoms. Straight or branched chain alkyl groups having hydrogen atoms; acyloxy groups, haloalkyl groups, alkoxy groups substituted with an oxy group, an alkyloxy group, a halogen atom, a cyano group or a haloalkyl group; Linear or branched chain C 1 ~C 6 Alkyl groups; straight or is a branched alkenyl group; a straight or branched chain alkenyl group having a cycloalkyl group of 2 to 12 carbon atoms Branched alkynyl groups; arylalkyl groups; alkylaryl groups; and aryl groups. In a further embodiment, the hydrocarbyl and substituted hydrocarbyl groups are C 1 ~C 6 1 to 10 carbon atoms, optionally substituted with an alkoxy group Alkyl group having C 1 ~C 6 2 to 3, optionally substituted with alkoxy groups; An alkenyl group having 10 carbon atoms; C 1 ~C 6 Optionally substituted with alkoxy groups cyclohexyl; or C 1 ~C 6 Optionally substituted with alkoxy groups It may be a phenyl group.
[0030] In one embodiment, R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl butyl, isobutyl, pentyl, neo-pentyl, hexyl, n-octyl, 2-octyl, Methoxymethyl, Methoxyethyl, Methoxypropyl, Methoxyisopropyl, Methoxy Butyl, methoxyisobutyl, allyl, methallyl, crotyl, propargyl, cyclohexyl Cyl, benzyl, phenyl, cresyl, 2-chlorobutyl, trifluoroethyl, 2-methyl 3-methoxybutyl, 2-ethoxyethyl, and 2-propoxyethyl is selected from.
[0031] organic part R 6 can be substituted or unsubstituted and can be linear, branched or It can be cyclic, saturated, unsaturated or aromatic. The organic part is C 1 ~C 8 Alkyl moiety, C 2 ~C 8 Alkenyl moiety, C 2 ~C 8 Al Quinyl moiety, C 3 ~C 12 alicyclic moieties, aryl moieties such as phenyl and substituted phenyl; and arylalkyl moieties such as benzyl, methylbenzyl, and phenylethyl. Other organic moieties include halo (e.g., chloro-, fluoro-, and bromo-substituted hydrocarbons). ) and oxy- (e.g., alkoxy-substituted hydrocarbon) substituted hydrocarbon moieties. In still further embodiments, R 6 is an acyclic alkyl group having 1 to about 8 carbon atoms; alkyl, alkenyl or alkynyl moieties, and their halo-substituted derivatives. In yet a further embodiment, R 6 is an alkyl moiety of 4 to 8 carbon atoms There can be.
[0032] In various embodiments, R 1 is an alkyl group having 1 to 10 carbon atoms or a group of the formula -A OR 7 [wherein A is a divalent linear or branched alkyl group having 2 to 8 carbon atoms] is an alkylene or oxyalkylene moiety, R 7 is a straight chain having 1 to 8 carbon atoms or a branched alkyl moiety. In a further embodiment, the cyanoacrylate The ingredients are 2-octyl cyanoacrylate, dodecyl cyanoacrylate, 2-ethylhexyl Xyl cyanoacrylate, butyl cyanoacrylate, methyl cyanoacrylate, 3 -Methoxybutyl cyanoacrylate, 2-butoxyethyl cyanoacrylate, 2-isopropyl isopropoxyethyl cyanoacrylate or 1-methoxy-2-propyl cyanoacrylate acrylate, methyl cyanoacrylate, ethyl cyanoacrylate, propyl cyanoacrylate acrylate, butyl cyanoacrylate, pentyl cyanoacrylate, hexyl cyanoacrylate Acrylate, Septyl Cyanoacrylate, Octyl Nonyl Cyanoacrylate, Decyl 2-Cyanoacrylate, Allyl Cyanoacrylate, Methoxyethyl Cyanoacrylate , methoxyisopropyl cyanoacrylate, methoxypropyl cyanoacrylate, Methoxybutyl cyanoacrylate or methoxypentyl cyanoacrylate, The cyanoacrylate component is a mixture of two or more methoxy cyanoacrylates. The copolymer may include a rate monomer.
[0033] The cyanoacrylate monomers disclosed herein are known in the art. It can be prepared by known methods, for example, U.S. Pat. No. 2,721,858; Nos. 3,254,111, 3,995,641 and 4,364,876 See, e.g., US Pat. No. 6,393,363, each of which is incorporated by reference for cyanoacrylate synthesis. The present disclosure relates to cyanoacrylates, the disclosure of which is incorporated herein in its entirety. The monomer may be an alkyl, cycloalkyl, halogenated, alkenyl or alkoxy group. Aliphatic 2-cyanoacrylates, including but not limited to alkyl 2-cyanoacrylates The alkyl group may have 1 to 16 carbon atoms, 2 to 8 carbon atoms or It may have 1 to 4 carbon atoms. Suitable esters include methyl esters such as cyanoacrylate, Ethyl, n-propyl, isopropyl, isobutyl, n-butyl, sec-butyl, n- Pentyl, isopentyl, n-hexyl, isohexyl, 2-ethylhexyl, cyclohexyl xyl, n-heptyl, n-octyl, 2-octyl, 2-methoxyethyl, methoxypropyl propyl, 2-ethoxyethyl and 2-methoxyisopropyl esters. For use in in vivo applications, the monomers utilized are of high purity.
[0034] For example, the cyanoacrylate component may comprise: a) about 80.0 wt. % of the cyanoacrylate component; , 80.5wt%, 81wt%, 81.5wt%, 82wt%, 82.5wt%, 83w t%, 83.5wt%, 84wt%, 84.5wt%, 86wt%, 86.5wt%, 8 7wt%, 87.5wt%, 88wt%, 88.5wt%, 89wt%, 89.5wt% , 90wt%, 90.5wt%, 91wt%, 91.5wt%, 92wt%, 92.5w t%, 93wt%, 93.5wt%, 94wt%, 94.5wt%, 96wt%, 96. 5wt%, 97wt%, 97.5wt%, 98wt%, 98.5wt%, 99wt%, 9 9.5wt%, or 80 to 99.5wt%, 80 to 95wt%, 80 to 81w t%, 80 to 82wt%, 80 to 85wt%, 84 to 86wt%, 85 to 87wt t%, 86 to 88wt%, 87 to 89wt%, 88 to 90wt%, 90 to 92wt t%, 91 to 93wt%, 90.5 to 92.5wt%, 91 to 93wt%, 92 to to 94wt%, 93 to 95wt%, 95.5 to 97.5wt%, 94 to 96wt% , 95 to 98wt%, 96 to 99wt%, 90 to 97wt%, 90 to 95wt% and may comprise within the range of 90 to 99.9 wt.%, up to about 100 wt.% of the composition. and all ranges between 80wt% and 100wt%.
[0035] In some embodiments, the cyanoacrylate component is a wt Blends or mixtures of two or more cyanoacrylate monomers within the % and / or range For example, one cyanoacrylate monomer is methyl cyanoacrylate. and when the second cyanoacrylate monomer is ethyl cyanoacrylate, A blend of cyanoacrylate monomers and ethyl cyanoacrylate monomers or The blend may form a cyanoacrylate component such as those disclosed herein. In some embodiments, the cyanoacrylate component is a cyanoacrylate copolymer disclosed herein. % and / or range of a single cyanoacrylate monomer. For example, When the cyanoacrylate monomer is methyl cyanoacrylate, The acrylate monomer may be a cyanoacrylate component such as those disclosed herein. Form.
[0036] In some embodiments, the stabilizer component of the cyanoacrylate composition is an anionic stabilizer. Examples of stabilizer components include the following: alkyl sulfides, alkyl sulfates, alkyl sulfurs, etc. alkyl sulfone, alkyl sulfoxide, alkyl sulfite lfites), sultones (e.g., a-chloro-a-hydroxy-o-toluenesulfonyl Sulfur dioxide, sulfur trioxide, sulfonic acid, lactone, boron trifluoride Organic acids such as acetic acid, 3-sulfolene, mercaptans, etc., and mixtures thereof. In certain applications, the stabilizer component may be sulfur dioxide, sulfur trioxide, or the like. yellow or sulfonic acid, or a combination thereof.
[0037] In one embodiment, the cyanoacrylate composition comprises hydrogen sulfide, carbonic acid, triacetyl methacrylate, acetic acid, lactic acid, benzoic acid, dinitrophenol, formic acid, nitrous acid, hydrochloric acid, hydrobromic acid, Hydrofluoric acid, chloroacetic acid, phosphoric acid (including ortho-, meta-, or para-phosphoric acid), dichloro trichloroacetic acid, trinitrophenol (picric acid), trifluoroacetic acid, sulfur Acid, perchloric acid, toluenesulfonic acid, fluorosulfonic acid, etc., and mixtures thereof. An acidic stabilizer may be included and may be included in the cyanoacrylate composition.
[0038] The biodegradable cyanoacrylate composition may include one or more stabilizers, such as an anionic stabilizer and an acidic stabilizer. There may be more than one type of stabilizer.
[0039] The stabilizer components have a concentration of about 500 to about 1,500 parts per million. In some embodiments, the stabilizer component can be present in an amount of from about 500 ppm to about 55 ppm. 0ppm, 500ppm to about 600ppm, about 500ppm to about 650ppm, about 5 00ppm to about 700ppm, about 500ppm to about 750ppm, about 500ppm to to about 800 ppm, about 500 ppm to about 850 ppm, about 500 ppm to about 900 ppm pm, about 500 ppm to about 950 ppm, about 500 ppm to about 1000 ppm, about 5 00ppm to about 1100ppm, about 500ppm to about 1200ppm, about 500ppm m to about 1300 ppm, about 500 ppm to about 1400 ppm, or about 500 ppm In some embodiments, the stabilizer component is present in an amount of from about 1400 ppm to about 1500 ppm. pm to about 1500ppm, about 1300ppm to about 1500ppm, about 1200ppm from about 1500 ppm, from about 1100 ppm to about 1500 ppm, from about 1000 ppm About 1500ppm, about 900ppm to about 1500ppm, about 800ppm to about 150 0 ppm, about 700 ppm to about 1500 ppm, or about 600 ppm to about 1500 In some embodiments, the stabilizer component is present in an amount of greater than about 500 ppm. The stabilizer component is present in an amount greater than about 550 ppm, or greater than about 600 ppm. is about 500ppm, 525ppm, 550ppm, 575ppm, 600ppm, 62 5ppm, 650ppm, 675ppm, 700ppm, 725ppm, 750ppm, 775ppm, 800ppm, 825ppm, 850ppm, 875ppm, 900ppm m, 925ppm, 950ppm, 975ppm, 1,000ppm, 1,025ppm , 1,050ppm, 1,075ppm, 1,100ppm, 1,125ppm, 1,1 50ppm, 1,175ppm, 1,200ppm, 1,225ppm, 1,250ppm m, 1,275ppm, 1,300ppm, 1,325ppm, 1,350ppm, 1, 375ppm, 1,400ppm, 1,425ppm, 1,450ppm, 1,475p pm, or 1,500 ppm.
[0040] In some embodiments, the polymerization inhibitor component of the cyanoacrylate composition is a free radical inhibitor. A suitable agent for use as the polymerization inhibitor component is butyl hydroxyapatite. butylated hydroxy anisole(BHA);NMP( n-Methyl-pyrrolidone), Hydroquinone; Catechol; Hydroquinone monomethyl ether hindered phenols such as butylated hydroxyanisole and butylated hydroxyanisole; 4-ethoxyphenol Butylated hydroxytoluene (BHT, 2,6-di-tert-butyl butyl phenol); 4-Methoxyphenol (MP); 3-Methoxyphenol; 2-tert-Br 2,2-methylene-bis-(4-methyl-6- tert-Butylphenol), etc., and mixtures thereof. The polymerization inhibitor component is BHA or BHT.
[0041] The polymerization inhibitor component may be present in an amount from about 4,000 ppm to about 7,000 ppm. In one embodiment, the polymerization inhibitor component is present in an amount of from about 4,000 ppm to about 4,500 ppm. 0ppm, 4,000ppm to about 5,000ppm, about 4,000ppm to about 5,5 00ppm, about 4,000ppm to about 6,000ppm, about 4,000ppm to about 6 ,500 ppm, about 4,000 ppm to about 6,500 ppm, or about 4,000 ppm In one embodiment, the polymerization inhibitor component is present in an amount of about 4 ,500ppm to about 7,000ppm, about 5,000ppm to about 7,000ppm, Or in an amount of about 6,500 ppm to about 7,000 ppm. The polymerization inhibitor component is greater than about 4,000 ppm, greater than about 4,500 ppm, or or greater than about 5,000 ppm. The polymerization inhibitor component is present in an amount of about 4,000 ppm. m, 4,250ppm, 4,500ppm, 4,750ppm, 5,000ppm, 5, 250ppm, 5,500ppm, 5,750ppm, 6,000ppm, 6,250p pm, 6,500 ppm, 6,750 ppm, or 7,000 ppm. This can be done.
[0042] The biodegradable cyanoacrylate compositions contemplated by the present disclosure have properties such as viscosity, color, and radiopacity. It may contain additives necessary to impart desired properties, including brightness and others. For example, The compositions of the present disclosure contain at least one soluble polymer that imparts flexibility to the delivered polymerized material. The plasticizer preferably contains little or no moisture and is a plasticizer that is suitable for use in the composition. The polymerisation of the polymer should not be significantly affected. Suitable plasticisers are known in the art. and are disclosed in U.S. Pat. Nos. 2,784,127 and 4,444,933. No. 6,399,413, the disclosures of which are incorporated herein by reference in their entireties. Examples of suitable plasticizers are tributyl citrate (TBC), acetyl tributyl citrate ( ATBC), dimethyl sebacate, triethyl phosphate, tri(2-ethylhexyl)phos Phosphate, Tri(p-cresyl)phosphate, Glyceryl triacetate, Glyceryl Tributyrate, diethyl sebacate, diisodecyl adipate (DIDA), adipic acid Dioctyl myristate (DICA), isopropyl myristate, butyl stearate, laurin Acid, trioctyl trimellitate, dioctyl glutarate (DICG), dioctyl phthalate ethyl, acetyl tri-n-butyl citrate, etc., and mixtures thereof. In some embodiments, a suitable plasticizer is a polyethylene glycol (PEG) ethylene ... Steryl and capped PEG esters or ethers, glutaric acid polyesters and and polymeric plasticizers such as polyester adipic acid. The agents are butyl benzyl phthalate, dibutyl phthalate, diethyl phthalate, and dimethyl phthalate. dioctyl phthalate, trialkyl acyl citrate, di- and poly-hydroxy Benzoic acid esters of branched aliphatic compounds, tri(p-cresyl)phosphate, In some embodiments, the plasticizer may be one to one alkyl group. 0 carbon atoms. For example, acyl trialkyl acyl citrate is trimethyl O-acetyl citrate. , triethyl O-acetylcitrate, tri-n-propyl O-acetylcitrate, Tri-n-butyl O-acetylcitrate, Tri-n-pentyl O-acetylcitrate, Tri-n-hexyl O-acetyl citrate, Tri-methyl O-propionyl citrate , Tri-ethyl O-propionyl citrate, Tri-n-propyl O-propionyl citrate citrate, tri-n-butyl O-propionyl citrate, tri-n-pentyl O-propionyl onyl citrate, tri-n-hexyl O-propionyl citrate, tri-methyl O- Butyryl citrate, tri-ethyl O-butyryl citrate, tri-n-propyl O-butyryl citrate Tri-n-butyl O-butyryl citrate, Tri-n-pentyl O- butyryl citrate, tri-n-hexyl O-butyryl citrate, etc. In one embodiment, the plasticizer is tri-n-butyl O-acetyl citrate. In one embodiment, tributyl citrate, diisodecyl adipate and citric acid Acetyl tributyl acetate, when present, may comprise up to 30 weight percent ( The amount used may be adjusted by those skilled in the art using known techniques to reduce the amount of excess water required. can be determined without experimentation.
[0043] The compositions of the present disclosure are effective in reducing active formaldehyde concentration levels during decomposition. At least one biocompatible agent may be included (for compositions that are subject to in vivo degradation, Such compounds are referred to as "formaldehyde concentration reducing agents." Examples of aldehyde scavenger compounds are: sulfites, bisulfites, ammonium sulfites, Mononium salts, amines, amides, imides, nitriles, carbamates, alcohols; mercaptans Active methylene compounds such as benzene, proteins, and cyclic ketones, and compounds with b-dicarbonyl groups Certain heterocyclic compounds, etc., and mixtures thereof. Bisulfites and sulfites useful as formaldehyde scavengers are Examples of useful amines include aniline, benzene, Diamine, aminopyrimidine, toluene-diamine, triethylenediamine, diphenylamine Aliphatic and aromatic amines such as diaminodiphenylamine, hydrazine, and hydrazide Suitable proteins include collagen, gelatin, casein, and mixtures thereof. Proteins include cellulose, soy protein, vegetable protein, keratin, glue, etc., and mixtures thereof. Suitable amides are urea, cyanamide, acrylamide, benzamide and acetamide. Suitable alcohols include phenol, 1,4-butanediol, d-sorbitol, Examples of suitable compounds having a b-dicarbonyl group include polyvinyl alcohol and polyvinyl alcohol. , malonic acid, acetylacetone, ethylacetone, acetate, malonamide, malonic acid diethyl, or another malonate ester, and the like, and mixtures thereof.
[0044] The biodegradable cyanoacrylate compositions of the present disclosure are suitable for use in medical and veterinary applications. To improve practicality, it may contain one or more adjuvant substances such as thickeners, medicines, etc. That's fine.
[0045] Suitable thickeners are, for example, polycyanoacrylate, polylactic acid, poly-1,4-dioxane, poly(lactic acid), ... Sa-2-one, polyoxalate, polyglycolic acid, lactic acid-glycolic acid copolymer, Polycaprolactone, lactic acid-caprolactone copolymer, poly-3-hydroxybutyric acid, poly Polyorthoesters, polyalkyl acrylates, alkyl acrylates and vinyl acetates copolymers of polyalkyl methacrylate, polymethyl methacrylate, and alkyl Copolymers of alkyl methacrylate, butadiene, etc., and mixtures thereof. Examples of methacrylates and acrylates are poly(2-ethylhexyl methacrylate) and poly(2-ethylhexyl methacrylate). ) and poly(2-ethylhexyl acrylate), and poly(butyl methacrylate) and poly(butyl acrylate), and poly(butyl methacrylate-co-methyl acrylate). copolymers of various acrylate and methacrylate monomers, such as acrylate, and mixtures thereof. In one embodiment, the thickening agent is a compound as described in U.S. Patent Application Serial No. Cyanoacrylate partial polymers and and polyoxyethylene ethers disclosed in U.S. Patent Application Serial No. 12 / 214,794. In many applications, it is possible to use a triblock copolymer of sialic alkylene. The agent is desirably miscible in the cyanoacrylate monomer composition at room temperature. stomach.
[0046] In some embodiments, the biodegradable cyanoacrylate composition may comprise, with or without a thickener: Substantially prevents the liquid composition from flowing or dripping beyond the intended application site. For example, the compositions disclosed herein have a viscosity of 100 less than 50 cP, less than 30 cP, less than 20 cP, less than 15 cP, or about 10cps to about 20cP, about 10cP to about 30cP, or about 20cP From about 30 cP, from about 10 cP to about 40 cP, from about 20 cP to about 40 cP The viscosity may be within the range of 100 nm to 150 nm. Standards and instruments for this purpose are known. Biodegradable cyanoacrylate compositions are premixed. Since the initial biodegradable cyanoacrylate composition is provided sterile, it is biodegradable after sterilization. Cyanoacrylate compositions or their end of useful life and / or shelf life The initial viscosity of the biodegradable cyanoacrylate composition may be lower than that of the biodegradable cyanoacrylate composition adjacent thereto. The mixed sterilized biodegradable cyanoacrylate composition has a viscosity of 19 cP or less, or 18 cP or less. or 17 cP or less, 16 cP or less, or 15 cP or less. For mixed, sterilized, biodegradable cyanoacrylates some time after their usable shelf life The rate composition is 30 cP or less, or 29 cP or less, or 28 cP or less, or 27 cP or less or below 26cP, below 25cP, below 24cP, below 23cP, below 22cP, It may have a viscosity that is 21 cP or less, 20 cP or less.
[0047] Many known cyanoacrylate compositions must be kept separate until the moment of use. For example, polymerization occurs at the time of mixing and application of the composition is required until polymerization is completed rapidly. Since this must occur before completion, many adhesives require mixing two components and then This is necessary to prevent polymerization in the container in which it is provided. In order to do so, it is necessary to provide ampoules or separate containers for the ingredients.
[0048] Unlike these cyanoacrylate compositions, the biocompatible compositions disclosed herein The biodegradable cyanoacrylate composition is provided in one container. The cyanoacrylate component is provided in a mixture as described above, wherein the cyanoacrylate component is a stabilizing component and It is supplied in one container with other ingredients such as a polymerisation inhibitor and a biodegradable cyanoacrylate. Initiate polymerization, which must be performed by the user prior to application of the related composition to the target site. There is no mixing to separate the cyanoacrylate components. The mixing conditions of the disclosed compositions may include an acrylate monomer to initiate polymerization. In contrast to cyanoacrylate compositions which must be mixed immediately at the time of use to For illustrative purposes, they may be referred to herein as "premixed." If a user wishes to add ingredients such as sonolucent particles to a biodegradable cyanoacrylate composition, For example, the particles may be mixed into a biodegradable cyanoacrylate composition. It is not carried out to initiate polymerization of the acrylate monomers.
[0049] In some embodiments, the biodegradable cyanoacrylate compositions disclosed herein The article may be prepared by providing the composition in a container, such as the containers disclosed herein. , may be provided in a liquid state. A reactive cyanoacrylate composition, for example, is prepared by mixing two cyanoacrylate monomers. The composition is formulated in an unpolymerized state and remains liquid during shipping and storage until use. The biodegradable cyanoacrylate composition remains in a water-containing environment, such as a body cavity or surface. The biodegradable cyanoacrylate composition disclosed herein remains in a liquid state until application to the The article has an extended shelf life and the composition meets the criteria and standards for use. For example, the biodegradable cyanoacrylate compositions disclosed herein have a shelf life of 0.5 years. 0.6 years or more, 0.7 years or more, 0.8 years or more, 0.9 years or more, 1.0 years or more or greater than 1.2 years, or greater than 1.5 years. The biodegradable cyanoacrylate compositions disclosed in the document have a shelf life of 0.5 years, 0.7 years, The biodegradable sheath may have a shelf life of 0.9 years, 1.0 years, 1.2 years, or 1.5 years. The non-acrylate composition is intended to be used for a period of time longer than health care regulations permit the composition to be provided. The adhesive strength of the formed biodegradable cyanoacrylate composition can be improved. To improve the adhesion, cross-linking agents known in the art may be added. ,362, which is incorporated herein by reference.
[0050] For certain applications, the biodegradable cyanoacrylate composition may contain small amounts of dye or facial The ink may further contain a coloring agent such as a dye. Suitable dyes include derivatives of anthracene and other complexes. Combination structures, specifically, but not limited to, 1-hydroxy-4-[4-methylphenyl]a Amino]-9,10-anthracenedione (D&C violet No.2); 9-(o- (carboxyphenyl)-6-hydroxy-2,4,5,7-tetraiodo-3H-xanthene 6-Hydroxy-3-one, disodium salt, monohydrate (FD&C Red No. 3); Dinatrium-5-[(4-sulfophenyl)axo]-2-naphthalene-sulfonic acid 2-(1,3-dihydro-3-oxo- 5-Sulfo-2H-indol-2-ylidene)-2,3-dihydro-3oxo-1H- Indanol-5 sulfonic acid disodium salt (FD&C Blue No. 2); and and 1,4-bis(4-methylanilino)anthracene-9,10-dione (D&C Group In some embodiments, the dye includes D&C Violet No. 2, FD&C Blue No. 2, and D&C Green No. 6.
[0051] In some embodiments, the biodegradable cyanoacrylate composition is used for imaging using ultrasound, fluoroscopy or other imaging modalities. sonolucent or radiolucent so that the occlusion can be monitored by radiological or x-ray techniques. It may include radiopaque compounds or particles.
[0052] In some embodiments, the biodegradable cyanoacrylate composition comprises alkylparabens and Salt, Ethylparaben, Methylparaben, Sodium Methylparaben, Propylparaben Additional stabilizing or preservatives such as sodium, propylparaben, and butylparaben are also included. Other suitable preservatives include hydroquinone, pyrocatechol, resorcinol, 4-n-hexylresorcinol, benzoic acid, benzyl alcohol, chlorobutanol , dehydroacetic acid, o-phenylphenol, phenol, phenylethyl alcohol, Potassium benzoate, potassium sorbate, sodium benzoate, sodium dehydroacetate , sodium propionate, sorbic acid, thimerosal, thymol, cresol, boric acid Includes phenylmercury and phenylmercuric compounds such as phenylmercury nitrate.
[0053] In some embodiments, the biodegradable cyanoacrylate composition further comprises an effective amount of an antimicrobial agent. Suitable antibacterial agents include antibacterial agents such as chlorhexidine and its salts, typically Antibiotics, vinylpyrrolidone and vinyl acetate copolymers, preservatives, povidone-iodine, etc. Iodine-containing polymers, biguanidine compounds, 5-chloro-2-(2,4-dichlorophenyl) Phenolic compounds such as (oxy)phenol, acridine compounds, benzalkonium chloride, etc. Quaternary ammonium compounds, cetyl pridospore and zephyran, polyisocyanates copolymers of vinylpyrrolidone and vinyl acetate crosslinked with dimethylformamide; heavy metal salts such as silver nitrate; as well as aldehyde compounds such as glutaraldehyde.
[0054] For certain applications, the biodegradable cyanoacrylate composition can be degraded by heat, light, or the action of Adding a polymerization initiator or accelerator that is activated by other modifications upon delivery to the site Such initiators and accelerators are known in the art. See US Pat. No. 6,143,805, which is incorporated herein by reference. For example, polymerization accelerators include calixarenes and oxacalixarenes, Silacrown, crown ether, cyclodextrin and its derivatives, polyether , aliphatic alcohols, various aliphatic carboxylic acid esters, benzoyl peroxide, triethyl Amines, diethylamine, butylamine, isopropylamine, tributylamine, N, N,N-Dimethylaniline, N,N-Diethylaniline, N,N-Dimethyl-p-toluidine N,N-dimethyl-m-toluidine, N,N-dimethyl-o-toluidine, dimethyl Benzylamine, pyridine, picoline, vinylpyridine, ethanolamine, propanoate amine compounds such as alkylamine and ethylenediamine; alkylammonium salts; Ammonium salts with alkoxy bonds, ammonium salts with ester bonds, ammonium salts with ether bonds and and alkyl imidazolinium salts, quaternary ammonium salts, cyclosulfur compounds and derivatives. The copolymer may be selected from polyalkylene oxides and derivatives.
[0055] In some embodiments, a crown ether as an accelerator is used in a cyanoacrylate composition. Examples of crown ethers include 15-crown-5, 18-crown-6, Dibenzo-18-crown-6, Tribenzo-18-crown-6, Dicyclohexyl 18-crown-6, benzo-15-crown-5, dibenzo-24-crown-8, dibenzyl Benzo-30-crown-10, asym-dibenzo-22-crown-6, dimethylsilyl -11-crown-4, dimethylsila-14-crown-5, dimethylsila-17-crown dibenzo-14-crown-4, dicyclohexyl-24-crown-8, as ym-Dibenzo-22-crown-6, cyclohexyl-12-crown-4, 1,2- Decalyl-15-crown-5, 1,2-naphtho-15-crown-5, 3,4,5-naphtho 1,2-methyl-benzo-18-crown-6, 1,2- Methylbenzo-5,6-methylbenzo-18-crown-6, 1,2-t-butyl-18 -Crown-6, 1,2-vinylbenzo-15-Crown-5, 1,2-vinylbenzo- 18-crown-6, 1,2-t-butyl-cyclohexyl-18-crown-6, and and 1,2-benzo-1,4-benzo-5-oxygen-20-crown-7. The present invention is not limited to these.
[0056] In one embodiment, the amount of polymerization accelerator added to the cyanoacrylate composition is about 10 For example, the polymerization accelerator is present in an amount of about 4 ppm to 6000 ppm of the liquid adhesive composition. 0 ppm to 5000 ppm, more preferably about 60 ppm to 4000 ppm. The amount of polymerization accelerator used can be determined by one of ordinary skill in the art using known techniques. This can be determined without undue experimentation.
[0057] While not wishing to be bound by any particular theory, the disclosed biodegradable cyanoacrylates The composition is, for example, a bilayer formulation for application to both the epithelial layer and the muscular layer of the fallopian tube of a body duct such as the fallopian tube. These layers of the body are thought to induce a cellular and / or tissue response in the ducts. and the chemical and physical contact induced fine grains of polymerized cyanoacrylate compositions. Cell and / or tissue reactions may occur over a period ranging from several weeks to several months. While performing its long-term function on tissues, biodegradable cyanoacrylate The plate composition gradually decomposes. Without wishing to be bound by any particular theory, it is believed that the decomposition process The process is believed to begin at the interface of the solidified (polymerized) composition and the epithelial layer. In addition, the chemical bonds of the polymerized composition in the epithelial layer are encapsulated by the secretory cells of the mucous membrane and by moisture. This exposure occurs at the polymerized stage. With the decomposition and elimination of the polymerized composition, the exposed Exposed and reacting muscle layers, e.g., on opposite sides of the duct, are in direct contact with each other and are heated. When heated, they anneal together to form a permanent occlusion, sealing off the conduit. The anoacrylate forms an initial blockage of the duct, while the cyanoacrylate composition decomposes and Although it leaves the duct, the affected tissue forms a persistent blockage.
[0058] While not wishing to be bound by any particular theory, the cyano compounds disclosed herein may be Acrylate compositions are believed to degrade primarily by ester hydrolysis. Methoxypropyl cyanoacrylate is a cyanoacrylate that decomposes via a chain scission degradation pathway. Shalaby and Shalal have shown that cyanoacrylates are more hydrophilic than acrylates. aby(Chapter 5, Cyanoacrylate-based Systems as T issue Adhesives.Absorbable and Biodegrad (Corporate Qualified Polymers, 2004, CRC Press LLC) Methoxypropyl cyanoacrylates were found to be hydroxylated to hydroxypropyl acrylates under hydrolysis of their ester groups. Produces water-soluble by-products without the formation of aldehydes. Polymerization of the esters occurs via hydrolysis of the pendant ester groups of the chain and the formation of water-soluble, excretable by-products. Some by-products are alcohols, there is no detectable acetate production, and and / or very low levels of formaldehyde.
[0059] The biodegradable cyanoacrylate composition can be used on any material made of plastic, aluminum or glass. may be placed in and stored in containers, including but not limited to containers manufactured by Examples of containers are pouches, vials, swabs or abutments on the container that hold the composition therein. Applicators such as applicator tips, ampoules, syringes, pipettes, and shears These include components of medical devices capable of delivering the acrylate composition. Not limited to.
[0060] The article of the present disclosure comprises the biodegradable cyanoacrylate composition disclosed herein. For example, the article (e.g., the biodegradable cyano disclosed herein) may be The container containing the acrylate composition may be a component of a medical device. Such medical device container components also contain cyanoacrylate compositions. The cyanoacrylate compositions of the present disclosure may be sterilized in an unpolymerized state. and when applied to a body surface such as a mucous membrane, , polymerization of the cyanoacrylate monomer proceeds.
[0061] Such articles, containers of the disclosed biodegradable cyanoacrylate compositions, are suitable for use in medical devices. The kit of the present disclosure may include the disclosed biodegradable shea Articles and medical devices containing cyanoacrylate compositions, e.g., biodegradable cyanoacrylates The article may include a medical device capable of delivering the composition. A desiccant may be provided within the container. For example, the desiccant may be silica gel. or for biodegradable cyanoacrylate compositions, water soluble over at least the shelf life period. Other known desiccants capable of absorbing water may be used. Silica gel is a type of sodium silicate. Silica is a granular, glassy, porous form of silicon dioxide made synthetically from silica. Most uses of the gel require it to be dried, and in this case this is the silica xenon. For practical purposes, silica gel is often called silica xerogel. The molecular sieve is provided in a container of the biodegradable cyanoacrylate composition. Another example of a desiccant-like material.
[0062] The desiccant may be provided in any suitable container. For example, the desiccant may be a high wet strength The polyethylene fiber sheet is permeable to both gases and odors. An example is Tyvek® from DuPont, which is suitable Suitable desiccants include, for example, Sigma-Aldrich, St. Louis, MO63,17 8, USA. For example, a pouch may contain 1 gram of desiccant, It can adsorb a minimum of 25% of its weight or 0.25 g.
[0063] In some embodiments, the biodegradable cyanoacrylate compositions disclosed herein Containers of goods include containers containing polymeric materials. For example, such containers may be made of polypropylene. It is made from, or at least backed by, a propylene (PP) heterophasic block copolymer. Such materials are available from Borealis, Wagramer Str asse 17-19, 1220 Vienna, Austria. The disclosed biodegradable cyanoacrylate composition comprises a plunger and optionally a cyanoacrylate. The syringe body is made of polypropylene similar to the syringe body, with a cap for sealing the other end of the syringe body. The plunger may be provided in a polyethylene or polypropylene copolymer cylindrical container. At least a portion of the material that will come into contact with the biodegradable cyanoacrylate composition is biodegradable. The composition does not adhere to the biodegradable cyanoacrylate composition and does not polymerize the biodegradable cyanoacrylate composition. The plunger and / or the device may be made of a material that will not initiate or decompose. The contact portion may be made of plastic, for example PTFE. The cap closures on the ends (e.g., syringe outlets) are made of biodegradable cyanoacrylate composites. Materials that do not bond to the composition and do not initiate polymerization or decompose the biodegradable cyanoacrylate composition. For example, the cap closure and / or its contact portion may be made of , may be made from plastic, for example HDPE.
[0064] In an embodiment, the container in which the composition is packaged may be a single or multi-layer construction of various materials. In some embodiments, the biodegradable cyanoacrylate composition can be The innermost layer, which is in contact with the container, is made of a polymer or copolymer. The structure may be any combination of any materials suitable for storing and delivering a liquid adhesive composition. By way of example, suitable materials include polymers, copolymers, thermoplastic polymers, plastics, etc. These include metals such as acrylic, nitrile polymers and copolymers, and foils.
[0065] Suitable thermoplastic polymers include polyethylene (PE) and polypropylene (PP). Polyolefins, including but not limited to polyethylene terephthalate (PE Polyesters such as high density polyethylene (HDPE), high density cross-linked polyethylene (HDPE), etc. Polyethylene (HDXLPE), Cross-linked polyethylene (XLPE), Medium density polyethylene (MDPE) , Linear Low Density Polyethylene (LLDPE), Low Density Polyethylene (LDPE) and Ultra Very low density polyethylene (VLDPE), high molecular weight polyethylene (HMWPE), ultra low molecular weight Polyethylene (ULMWPE) and Ultra High Molecular Weight Polyethylene (UHMWPE), Polyethylenes of all classes are suitable. The cyanoacrylate composition may be provided in a suitable container, where suitable means Prior to providing the degradable cyanoacrylate composition to a moisture-containing environment, the biodegradable cyanoacrylate is By "polymerization" is meant a container that does not polymerize or allow the rate composition to polymerize.
[0066] The biodegradable cyanoacrylate composition is placed in a suitable container. Without wishing to be bound, the cyanoacrylate composition may be and are self-sterilizing in that they do not need to undergo sterilization conditions to be safe and effective. To some extent, this disclosure relates to biodegradable cyanoacrylates that have or have not been subjected to sterilization conditions. For purposes of health care regulations, generally, The disclosed biodegradable cyanoacrylate compositions are provided after undergoing sterilization conditions. For example, after being placed in a suitable container, the biodegradable cyanoacrylate composition is then The containing container is sterilized.
[0067] In some embodiments, the biodegradable cyanoacrylate composition is referred to herein as a cyanoacrylate. A single cyanoacrylate compound or monomer, referred to as acrylate(s), is used. Contains a blend or mixture of cyanoacrylate compounds or monomers. For example, the cyanoacrylate component may contain one cyanoacrylate. acrylate, or more than one cyanoacrylate in a blend of cyanoacrylates The cyanoacrylate component of the present disclosure has short side groups, fast polymerization and and fast decomposition compared to methyl-2-cyanoacrylate, as well as the long side groups. , 2-octyl cyanoacrylate and butyl cyanoacrylate, which have slow polymerization and very slow decomposition Compared to the lactoyl cyanoacrylate blend, it has long side groups, relatively slow polymerization and It may include one or more cyanoacrylates, which have slow decomposition.
[0068] In one embodiment, the biodegradable cyanoacrylate composition comprises 30 wt% (±5%) of 2 -Butoxyethyl cyanoacrylate and 70wt% (±5%) pentyl cyanoacrylate Cyanoacrylate components consisting of acrylate and about 500 ppm to about 700 ppm A stabilizing component consisting of lactone in an amount of about 4000 ppm to 6000 ppm. and a polymerization inhibitor component made of nitrophenol.
[0069] In one embodiment, the biodegradable cyanoacrylate composition comprises 60 wt% (±5%) of nonaphthalene. Nyl cyanoacrylate and 40wt% (±5%) 2-octyl cyanoacrylate and a cyanoacrylate component consisting of from about 400 ppm to about 800 ppm of carbonate. and hydroquinone in an amount of about 4000 ppm to 6000 ppm. and a polymerization inhibitor component comprising:
[0070] In some embodiments, the biodegradable cyanoacrylate composition comprises 50 wt% (±5%) of n -Butyl-2-cyanoacrylate and 50wt% (±5%) of septyl cyanoacrylate and a cyanoacrylate component consisting of a cyanoacrylate in an amount of from about 400 ppm to about 800 ppm. The stabilizing component consists of sulfur dioxide in an amount of about 4000 ppm to 6000 ppm. and a polymerization inhibitor component consisting of ethyl hydroxyanisole.
[0071] In some embodiments, the biodegradable cyanoacrylate composition comprises 50 wt% (±5%) methacrylate. Methoxy-n-propyl cyanoacrylate and 50 wt% (±5%) methoxy-iso -propyl cyanoacrylate component, and approximately 500 ppm to A stabilizing component consisting of sulfur dioxide in an amount up to about 700 ppm and a range of sulfur dioxide from about 4000 ppm to 60 and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount up to 0.00 ppm.
[0072] In one embodiment, the biodegradable cyanoacrylate composition comprises 30 wt% (±5%) methacrylate. 70wt% (±5%) of methoxy-n-propyl cyanoacrylate and methoxy-iso -propyl cyanoacrylate component, and approximately 600 ppm to A stabilizing component consisting of sulfur dioxide in an amount up to about 700 ppm and a range of sulfur dioxide from about 5000 ppm to 60 and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount up to 0.00 ppm.
[0073] In some embodiments, the biodegradable cyanoacrylate composition comprises 70 wt% (±5%) methacrylate. 30% (±5%) of methoxy-n-propyl cyanoacrylate and 30% (±5%) of methoxy-iso -propyl cyanoacrylate component, and approximately 500 ppm to A stabilizing component consisting of sulfur dioxide in an amount up to about 700 ppm and a range of sulfur dioxide from about 4000 ppm to 60 and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount up to 0.00 ppm.
[0074] In one embodiment, the biodegradable cyanoacrylate composition comprises 40 wt% (±5%) of 2 -Isopropoxyethyl cyanoacrylate and 60wt% (±5%) pentyl cyanoacrylate A cyanoacrylate component consisting of about 600 ppm to about 700 ppm and a stabilizing component consisting of acetic acid in an amount of about 5000 ppm to about 7000 ppm. and a polymerization inhibitor component consisting of butyl hydroxyanisole.
[0075] In some embodiments, the biodegradable cyanoacrylate composition is greater than 95 wt. % or Cyanoacrylate is composed of more than 99 wt% methoxypropyl cyanoacrylate. and a stabilizing component consisting of sulfur dioxide in an amount of about 500 ppm to about 700 ppm. and butylated hydroxyanisole in an amount of about 4000 ppm to 7000 ppm. and a polymerization inhibitor component.
[0076] In some embodiments, the biodegradable cyanoacrylate composition is greater than 95 wt. % or Cyanoacrylate containing greater than 99 wt% methoxypropyl cyanoacrylate a stabilizing component comprising sulfur dioxide in an amount of from about 500 ppm to about 700 ppm; Polymerization containing butylated hydroxyanisole in amounts from about 4000 ppm to 7000 ppm and an inhibitor component.
[0077] In some embodiments, the biodegradable cyanoacrylate composition is greater than 95 wt. % or Cyanoacrylate is composed of more than 99 wt% methoxypropyl cyanoacrylate. and a stabilizing component consisting of sulfur dioxide in an amount of about 500 ppm to about 700 ppm. and butylated hydroxyanisole in an amount of about 4000 ppm to 7000 ppm. and a polymerization inhibitor component.
[0078] In some embodiments, the biodegradable cyanoacrylate composition is greater than 95 wt. % or Cyanoacrylate is made up of more than 99 wt% methoxyisopropyl cyanoacrylate. A stabilization step comprising a rate component and sulfur dioxide in an amount of about 500 ppm to about 700 ppm. and butylated hydroxyanisole in amounts ranging from about 4000 ppm to 7000 ppm. and a polymerization inhibitor component consisting of the following.
[0079] In some embodiments, the biodegradable cyanoacrylate composition is greater than 95 wt. % or Cyanoacrylate containing more than 99 wt% methoxyisopropyl cyanoacrylate and a stabilizing component consisting of sulfur dioxide in an amount of about 500 ppm to about 700 ppm. and butylated hydroxyanisole (B and a polymerization inhibitor component consisting of (HA).
[0080] In some embodiments, the biodegradable cyanoacrylate composition is greater than 95 wt. % or Cyanoacrylate is made up of more than 99 wt% methoxyisopropyl cyanoacrylate. A stabilization step comprising a rate component and sulfur dioxide in an amount of about 500 ppm to about 700 ppm. and butylated hydroxyanisole in amounts ranging from about 4000 ppm to 7000 ppm. and a polymerization inhibitor component comprising:
[0081] In some embodiments, the biodegradable cyanoacrylate composition comprises 70 wt% (±5%) methacrylate. methoxyisopropyl cyanoacrylate and 30% by weight (±5%) methoxyisopropyl A cyanoacrylate component consisting of cyanoacrylate and about 500 ppm to about 700 ppm pm, and the stabilizing component consisting of sulfur dioxide in amounts of about 4000 ppm to 7000 ppm. and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount up to 500 mg.
[0082] In some embodiments, the biodegradable cyanoacrylate composition comprises at least 70 wt% (± 5%) of methoxypropyl cyanoacrylate and at least 30 wt% (±5%) of Cyanoacrylate components including methoxyisopropyl cyanoacrylate and approximately 500p pm to about 700 ppm of sulfur dioxide, and a stabilizing component of about 4000 ppm and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount of from 0.1 to 7000 ppm. include.
[0083] In one embodiment, the biodegradable cyanoacrylate composition comprises 30 wt% (±5%) methacrylate. methoxyisopropyl cyanoacrylate and 70% by weight (±5%) methoxyisopropyl A cyanoacrylate component consisting of cyanoacrylate and about 500 ppm to about 700 ppm pm, and the stabilizing component consisting of sulfur dioxide in amounts of about 4000 ppm to 7000 ppm. and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount up to 500 mg.
[0084] In some embodiments, the biodegradable cyanoacrylate composition comprises at least 30 wt% (± 5%) of methoxypropyl cyanoacrylate and at least 70 wt% (±5%) of Cyanoacrylate components including methoxyisopropyl cyanoacrylate and approximately 500p pm to about 700 ppm of sulfur dioxide, and a stabilizing component of about 4000 ppm and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount of from 0.1 to 7000 ppm. include.
[0085] In some embodiments, the biodegradable cyanoacrylate composition comprises 50 wt% (±5%) methacrylate. methoxyisopropyl cyanoacrylate and 50% by weight (±5%) methoxyisopropyl A cyanoacrylate component consisting of cyanoacrylate and about 500 ppm to about 700 ppm pm, and the stabilizing component consisting of sulfur dioxide in amounts of about 4000 ppm to 7000 ppm. and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount up to 500 mg.
[0086] In some embodiments, the biodegradable cyanoacrylate composition comprises at least 50 wt% (± 5%) of methoxypropyl cyanoacrylate and at least 50 wt% (±5%) of Cyanoacrylate components including methoxyisopropyl cyanoacrylate and approximately 500p pm to about 700 ppm of sulfur dioxide, and a stabilizing component of about 4000 ppm and a polymerization inhibitor component consisting of butyl hydroxyanisole in an amount of from 0.1 to 7000 ppm. include.
[0087] In one embodiment, the biodegradable cyanoacrylate composition comprises 60 wt% (±5%) of 2 -Isopropoxyethyl cyanoacrylate and 40wt% (±5%) pentyl cyanoacrylate A cyanoacrylate component consisting of about 600 ppm to about 700 ppm and a stabilizing component consisting of acetic acid in an amount of about 5000 ppm to about 7000 ppm. and a polymerization inhibitor component consisting of catechol.
[0088] In some embodiments, the biodegradable cyanoacrylate composition comprises 50 wt% (±5%) of 2 -Isopropoxyethyl cyanoacrylate and 50wt% (±5%) pentyl cyanoacrylate A cyanoacrylate component consisting of about 600 ppm to about 700 ppm and a stabilizing component consisting of acetic acid in an amount of about 5000 ppm to about 7000 ppm. and a polymerization inhibitor component consisting of catechol.
[0089] The biodegradable cyanoacrylate compositions disclosed herein have the following functional characteristics: The method can be defined as: The cyanoacrylate composition may be subjected to one or all of the biocompatibility characterization tests (e.g., I SO standard) and pass cytotoxicity tests (e.g., ISO 10993- 5:2009)。 Biodegradable compositions of the present disclosure include compositions that fail the The cyanoacrylate composition comprises a cyanoacrylate component, a stabilizing component, and a polymerization inhibitor component. and sensitization (measured, for example, by ISO 10993-10:2010), Irritation (e.g. as measured by ISO 10993-10:2010), vaginal irritation (e.g. for example, as measured by ISO 10993-10:2010), heat generation (for example, I 10993-11:2010), systemic acute toxicity (e.g., I as measured by SO 10993-11:2010), systemic subchronic toxicity (e.g. genotoxicity (measured by, e.g., ISO 10993-11:2010); 10993-3:2003), rodent blood micronucleus assays (e.g. (measured by ISO 10993-3:2003) and mouse lymphoma mutagenesis 2 or more for development (e.g., as measured by ISO 10993-3:2003) Passed biocompatibility tests and cytotoxicity tests (e.g., ISO 10993-5:2009 Compositions used for human or animal treatment will fail the standard of care (measured by must pass these listed biocompatibility tests to be considered safe for use. Thus, in one embodiment, the disclosed biodegradable cyanoacrylate compositions are Each of these tests (sensitization, irritation, vaginal irritation, pyrogenicity, systemic acute toxicity, systemic subchronic toxicity) , genotoxicity, rodent blood micronucleus assay and mouse lymphoma mutagenesis), and cells It fails toxicity tests.
[0090] For example, the compositions disclosed herein for duct occlusion include cyanoacrylates. The composition contains a cytotoxicity test (e.g., ISO 1 0993-5:2009) and failed the biomarker test for genotoxicity. Passing a conformity test (e.g., as measured by ISO 10993-3:2003) The composition for occluding a duct comprises a cyanoacrylate component, a stabilizer component, and a polymerization inhibitor. Contains ingredients and is tested for cytotoxicity (e.g., as determined by ISO 10993-5:2009) For example, they may fail at least biocompatibility tests (e.g. For example, it passes ISO 10993-3:2003.
[0091] In some embodiments, the biodegradable cyanoacrylate compositions disclosed herein The composition has low viscosity compared to, for example, the known cyanoacrylate composition, Histoacryl. Aesculap AG, Am AESCULAP-Platz, D -78532 Available from commercial suppliers such as Tuttlingen / Donau, AT Histoacryl is a cyanoacrylate composition containing butyl cyanoacrylate In the example, a pigskin pouch was used to mimic the body ducts, and the biopsy was performed on the pigskin. The increase in temperature (here, heat of polymerization) observed after administration of the degradable cyanoacrylate composition is 1°C (i.e., approximately 0.7°C), whereas Histoacryl's temperature The increase in heat of polymerization (herein referred to as heat of polymerization) was 6.7° C. in one embodiment, e.g., The compositions disclosed herein for use in the preparation of a cyanoacrylate composition include a cyanoacrylate component and a stabilizer component. and a polymerization inhibitor component, and °C, less than 1 °C, or in the range from about 0.5 °C to about 6 °C and all values therebetween In some embodiments, the method of the present invention for example for occluding a conduit has a low heat of polymerization temperature within the range. The biodegradable cyanoacrylate composition disclosed in the document is a cyanoacrylate composition. The composition contains a polymerization inhibitor component, a stabilizer component, and a polymerization inhibitor component, and the composition is resistant to low temperatures within a range of 0.5°C to 1.0°C. The heat of polymerization is measured, for example, according to the differential equation based on ASTM D3418-12el. It may be measured by scanning calorimetry.
[0092] In some embodiments, the biodegradable compositions disclosed herein, e.g., for duct occlusion, are The cyanoacrylate composition comprises a cyanoacrylate component, a stabilizer component, and a polymerization inhibitor component. 10 minutes, which has a rapid in vitro hardening or setting time but does not emit harmful heat. Cure time or setting time refers to the rate of polymerization of at least a portion of the composition. For example, the biodegradable cyanoacrylate compositions disclosed herein were administered to porcine fallopian tubes. Full cure of the administered biodegradable cyanoacrylate composition was observed in 2 minutes. In some embodiments, the biodegradable cyanoacrylate compositions disclosed herein are The composition is preferably at least 10 seconds, at least 15 seconds, at least a portion of the administered composition. 20 seconds or more, 30 seconds or more, 40 seconds or more, 50 seconds or more, 60 seconds or more, 70 seconds or more 80 seconds or more, 90 seconds or more, 100 seconds or more, 110 seconds or more, or 120 seconds or more In some embodiments, the biodegradable silicones disclosed herein have a cure time of 100-250° C. The anoacrylate composition may be applied for 2 minutes or less, less than 110 seconds, less than 100 seconds, or less than 90 seconds. of, less than 80 seconds, less than 70 seconds, less than 60 seconds, less than 50 seconds, less than 40 seconds, 30 seconds having a cure time of less than 25 seconds, less than 20 seconds, less than 15 seconds, or less than 10 seconds In some embodiments, the biodegradable cyanoacrylates disclosed herein The composition has a cure time (or setting time) of between 10 and 120 seconds. me)).
[0093] In some embodiments, the biodegradable cyanoacrylate compositions disclosed herein The article, when polymerized, is flexible. Flexibility may be assessed by a free bending test, Here, the composition is polymerized into a rod and the rod is bent 180°. The extent of the damage is recorded by the fracture, surface condition and cracks of the rod. Polymerized rods of the biodegradable cyanoacrylate composition were stained with Histoacryl Blue ( The biodegradable cyanoacrylate polymerized rods disclosed were compared to those of butyl cyanoacrylate. The related composition was bent 180 degrees without damage or significant change, whereas the Histoa The cryl Blue rod broke into pieces before reaching the 180 degree bend. The biodegradable cyanoacrylate composition disclosed herein is a polymerizable Afterwards, it is flexible as measured by this test.
[0094] In some embodiments, the biodegradable compositions disclosed herein, e.g., for duct occlusion, are The cyanoacrylate composition comprises a cyanoacrylate component, a stabilizer component, and a polymerization inhibitor component. It contains a compound that has passed biocompatibility testing for at least genotoxicity and is cytotoxic. The biocompatibility test for the material failed, with a low temperature of 0.5°C to 1.0°C. It has a low polymerization temperature, a viscosity of 30 cP or less, and a hardening or setting time of between 10 and 30 seconds. and is flexible and has a shelf life of greater than 0.5 years, and optionally the composition is sterilized. It is okay to do so.
[0095] The biodegradable cyanoacrylate compositions of the present disclosure are useful in medical and veterinary applications. Biodegradable cyanoacrylate compositions for such applications include Preferably, it is sterile. Thus, the present disclosure relates to the sterile biodegradable compositions described herein. The biodegradable cyanoacrylate compositions disclosed herein include The acrylate composition may be sterilized by conventional techniques. Cyanoacrylate Adhesives Sterilization of the composition may be by methods including, but not limited to, chemical, physical and irradiation methods. Examples of chemical methods include, but are not limited to, exposure to ethylene oxide. Examples of irradiation methods include gamma irradiation, electron beam irradiation, and microwave irradiation. The preferred sterilization methods are chemical sterilization and electron beam sterilization. A suitable container containing the biodegradable cyanoacrylate composition shown is 10 to 20 kg. Sterilization may be achieved by electron beam processing at a dose of Gy. Such sterilization methods are well known in the art. This method is well known in the art and is taught, for example, by ISO 11137-2. The method includes at least a cyanoacrylate component, a stabilizer component, and a polymerization inhibitor component. The biodegradable cyanoacrylate composition may be applied to a body surface or to a site within the body, for example, to close a duct. Providing and / or administering or applying to or near a duct to cause it to become blocked In some embodiments, disclosed herein is a conduit, e.g. For example, an exemplary composition for the occlusion of the mammalian reproductive tract. In other physiological systems and biological sites of mice or other animals, such sites whether it is naturally there or has been created, for example, by surgical means may be used regardless, and such use is contemplated by this disclosure.
[0096] One aspect of the present disclosure is a method of contraception for a female mammal comprising administering to said mammal a biodegradable cyanoacrylate contraceptive. The composition is administered to a target site, for example, from the lateral horn of the uterus to each fallopian tube, where the viable fraction is The method includes the steps of: include.
[0097] One area where ductal occlusion is required is the control of fertility by occlusion of the oviduct. The main cause of spontaneous infertility in women is the closure of the fallopian tubes that connect the ovaries to the uterus. It is well known in the art that females with this natural condition are usually You won't even notice it and you won't suffer any harmful side effects other than infertility.
[0098] Based on observations of naturally occurring oviductal occlusion, the creation of oviductal occlusion by external intervention may result in female sterilization. In the early 1980s, the cyanoacrylate Anoacrylate compositions were used for female contraception by blocking the fallopian tubes. High levels of acid were utilized to stabilize the reactive cyanoacrylate. The problem is the difficulty of handling the methyl cyanoacrylate material, its lower than acceptable effectiveness, and Due to the efficiency and need for multiple uses of methyl cyanoacrylate materials, It never became commercially viable.
[0099] Utilizing the occlusion composition to create an occlusion in the fallopian tubes may be performed in its entirety. 8,048,086, 8,048,101, 8,052,66, all of which are incorporated herein by reference. 9, 8,316,853, 8,316,854, 8,336,552, 8,324,19 3, 8,695,606, 9,034,053, 8,726,906, 9,220,88 0 and applications claiming priority thereto, It would be ideal if it could be delivered non-surgically via a catheter. Non-surgical options for preventing ovarian failure are limited and involve permanent implants that can deposit in the fallopian tubes and create long-term blockages. The use of quinacrine has been shown to cause scarring of the fallopian tube epithelium, leading to tubal occlusion. It has been well established that the peritoneal cavity cannot contain the blood vessels, allowing them to flow out into the peritoneal cavity. This has significant limitations in that
[0100] For example, in certain embodiments, the method includes administering a catheter or one or more catheters A liquid biodegradable synovial solution is delivered to the uterine horn and to the fallopian tubes using a delivery system comprising The method includes the step of delivering an effective amount of an anoacrylate composition disclosed herein. The biodegradable cyanoacrylate composition is delivered in an amount of about 0.3 to 1.0 mL. The cyanoacrylate composition may be 0.3, 0.4, 0.5, 0.6, 0 0.7, 0.8, 0.9, 1.0 mL may be delivered. Larger or smaller amounts may be delivered. However, the method should not involve filling the entire fallopian tube, but rather, for example, focusing only on the interstitial (intramural) portion of the tube. The aim is to deliver the drug to the smallest area and create an occlusion in the proximal portion of the fallopian tube. The biodegradable cyanoacrylate composition is resistant to cyanoacrylate and cyanoacrylate-based steroids upon contact with tissues and fluids within the uterine cavity and fallopian tubes. The biodegradable cyanoacrylate composition is a polymerized cyanoacrylate. The chemical bonding and physical contact of the relase composition primarily binds to the epithelial lining and The biodegradable cyanoacrylate composition is believed to adhere to the luminal periphery of the epithelium. It occupies space within a structure.
[0101] The biodegradable cyanoacrylate composition is applied to the target area during and after the polymerization process. This is due, in part, to the fact that the cyanoacrylate composition is May be by delivering in a controlled (e.g., slow) manner and in discrete volumes One of ordinary skill in the art would understand how to deliver the polymerizable composition.
[0102] The disclosed biodegradable cyanoacrylate compositions are effective in the epithelial lining of the fallopian tube and in Both are thought to induce cellular and / or tissue inflammatory responses against the muscular layer of the fallopian tube. Cellular and / or tissue reactions occur due to chemical and physical contact with the surrounding lining of the fallopian tube. Long-lasting cellular and / or tissue reactions can be induced by In particular, the muscular layer of the fallopian tube, which regenerates more slowly than the endometrium, has a shorter duration of cell damage. Prevents the typical regenerative healing process that can occur over a period of time. Without effective fibrinolysis, reactive tissue does not heal functional tissue, but instead produces non-functional scar tissue. The polymerized biodegradable cyanoacrylate composition is then absorbed into the tissue over the course of several weeks. During the course of providing a long reaction time, the biodegradable cyanoacrylate composition slowly decomposes. Over time, the surface bonds of the polymerized biodegradable cyanoacrylate composition are enhanced by the mucosal This means that the body is continuously exposed to the moisture and secretions produced by the secretory cells. This exposure leads to the gradual breakdown and removal of the biodegradable cyanoacrylate composition. When the biodegradable cyanoacrylate composition is removed from the area of the fallopian tube, luminal occlusion occurs. The occlusion occurs due to occlusion and scarring. As it decomposes, the degradation products and / or solid pieces of polymerized material that break off are released into the fallopian tubes. Movement by fluid and preuterine cilia toward the uterine cavity and then out of the vagina It is predicted to be.
[0103] Biodegradable cyanoacrylate compositions delivered non-surgically via an intrauterine catheter - Patents.com To provide successful tubal occlusion with:
[0104] A biodegradable sheath that remains in liquid form when stored before and after sterilization and during delivery. The cyanoacrylate composition, and therefore the biodegradable cyanoacrylate composition, is stably formulated. be cured without premature polymerization;
[0105] The biodegradable cyanoacrylate composition is directed to or within a target site, such as the fallopian tube. of suitable viscosity to travel via and be delivered by the intrauterine catheter It is good to have;
[0106] Upon delivery to the target site, such as the fallopian tube, the biodegradable cyanoacrylate composition may polymerize rapidly, e.g., within seconds, to prevent movement from the fallopian tube;
[0107] The resulting cured polymer (polymerized biodegradable cyanoacrylate composition material) can be used as a topical A reaction may be elicited while the polymer begins to degrade, break down and / or disintegrate;
[0108] The resulting cured polymer (polymerized biodegradable cyanoacrylate material) lacks durability. The fact that the cyanoacrylate composition may become detached from the conduit over time is a sign of its incompatibility with the cyanoacrylate composition. allowing for durable occlusion due to the duct's response and healing response;
[0109] The biodegradable cyanoacrylate composition is administered and the resulting cured composition is non-toxic. The occlusive composition is biocompatible with the subject to which it is applied, but is not harmful to other cells, such as sperm. obtain.
[0110] The biodegradable cyanoacrylate composition may be sonolucent in nature or may be Alternatively, sonolucency may be achieved by the introduction of bubbles, such as microbubbles of air or gas, into the material. These microbubbles may be present in a composition, Or it may be present when the composition polymerizes into a solid form.
[0111] The method disclosed herein includes applying a biodegradable cyanoacrylate composition to an occlusion site. and administering the cyanoacrylate composition to or near the site. and polymerizing the occlusion site in situ. The method may further include testing that occlusion of the site has occurred. A delivery device for delivering a cyanoacrylate composition to one or more mammalian fallopian tubes may be provided. Methods for achieving this are described in U.S. Patent Nos. 8,048,086, 8,048,101, and 8,051. No. 2,669, No. 8,316,853, No. 8,316,854, No. 8,336 , No. 552, No. 8,324,193, No. 8,695,606, No. 9,034, Nos. 053, 8,726,906, 9,220,880, and the corresponding claims thereto No. 6,313,633, filed on Oct. 13, 2003, and claims priority from the same application, each of which is incorporated herein in its entirety. Methods for evaluating the fallopian tubes are known in the art and are described in U.S. Pat. 9,554,826 and / or USSN 13 / 292,990; The two catheters are made of biodegradable sheaths. The same biodegradable cyanoacrylates are used in the method of delivery of the cyanoacrylate composition. Two containers of the composition may be provided, for example two syringes.
[0112] Packaging and sterilization
[0113] In the compositions and methods disclosed herein, a biodegradable cyanoacrylate The composition may be provided sterile. If sterilization techniques are performed on the packaged composition, In such cases, it would be desirable to be able to transport the sterilized composition in a sterile state upon sterilization. Compositions containing anoacrylate esters often undergo oxidative stress upon contact with tissue or fluids. Polymerization begins instantly and often occurs rapidly.
[0114] The biodegradable cyanoacrylate composition does not react with the biodegradable cyanoacrylate composition. , does not cause premature polymerization, i.e., polymerization before the composition is delivered to the target site. , may be provided in a container. Examples of containers of suitable materials are disclosed herein. .
[0115] kit
[0116] The present disclosure relates to a method for producing a biodegradable cyanoacrylate composition disclosed herein that is contained within a container. The kit further comprises a rate composition, and optionally a desiccant. The compositions disclosed herein may further comprise a biodegradable shea. The composition may be provided in a kit together with a medical device for delivery. Such kits also include instructions for use of the medical device and the biodegradable cyanoacrylate composition. The kit may include a biodegradable cyanoacrylate in a suitable container, which may optionally further include a desiccant. and a medical device for delivering the biodegradable cyanoacrylate composition. The medical device may include instructions for use of the composition and the medical device.
[0117] Disclosed herein are compositions, including biodegradable cyanoacrylate compositions. The disclosed biodegradable cyanoacrylate compositions, methods, articles, kits and medical devices. The rate composition comprises: a) a cyanoacrylate composition comprising at least one cyanoacrylate; % or more by weight of a cyanoacrylate component; and b) 500 ppm to 1 stabilizer components in the range of up to 500 ppm; and c) in the range of 4000 to 7000 ppm. The disclosed biodegradable cyanoacrylate composition contains a polymerization inhibitor component. The anoacrylate component comprises at least two cyanoacrylate monomers. The composition may include a reactive cyanoacrylate composition.
[0118] The disclosed biodegradable cyanoacrylate composition comprises a cyanoacrylate monomer , methyl cyanoacrylate, ethyl cyanoacrylate, propyl cyanoacrylate , butyl cyanoacrylate, pentyl cyanoacrylate, hexyl cyanoacrylate Septyl cyanoacrylate, Octyl nonyl cyanoacrylate, Decyl 2-cyanoacrylate Noacrylate, Allyl Cyanoacrylate, Methoxyethyl Cyanoacrylate, Meth Methoxyisopropyl cyanoacrylate, Methoxypropyl cyanoacrylate, Methoxy Butyl cyanoacrylate, methoxypentyl cyanoacrylate, or a combination thereof The composition may include a biodegradable cyanoacrylate composition.
[0119] The disclosed biodegradable cyanoacrylate composition has a stabilizer component that is an alkyl sulfonate. Fide, alkyl sulfate, alkyl sulfonyl, alkyl sulfone, alkyl sulfonate oxides, alkyl sulfites, sultones, sulfur dioxide, sulfur trioxide, sulfonic acids, lactones, Boron trifluoride, acetic acid, or 3-sulfolene, mercaptan, or combinations thereof The disclosed biodegradable cyanoacrylate compositions may include The noacrylate composition is a biodegradable composition in which the stabilizer component comprises sulfur dioxide or sulfur trioxide. It may include a cyanoacrylate composition.
[0120] The disclosed biodegradable cyanoacrylate composition contains a polymerization inhibitor component, such as butyl hydride. BHA; Hydroquinone; Catechol; Hydroquinone monomethyl ether Hindered phenols such as tert- and butylated hydroxyanisole; 4-ethoxyphenols Butylated hydroxytoluene (BHT, 2,6-di-tert-butyl butyl phenol) phenol), 4-methoxyphenol (MP); 3-methoxyphenol; 2-tert- Butyl-4-methoxyphenol; or 2,2-methylene-bis-(4-methyl-6 -tert-butylphenol), or a combination thereof. The disclosed biodegradable cyanoacrylate compositions may include polymerizable cyanoacrylate compositions. The inhibitor component includes a biodegradable cyanoacrylate composition that includes BHA or BHT. good.
[0121] The disclosed biodegradable cyanoacrylate composition is a cyanoacrylate composition that is free of hydrogen sulfide, carbonate, triacetyl, and acetylated acrylate. Methane, acetic acid, benzoic acid, dinitrophenol, formic acid, nitrous acid, hydrochloric acid, hydrobromic acid, fluorine Hydrochloric acid, chloroacetic acid, phosphoric acid, dichloroacetic acid, trichloroacetic acid, trinitrophenol , trifluoroacetic acid, sulfuric acid, perchloric acid, toluenesulfonic acid or fluorosulfonic acid , or a combination thereof.
[0122] The disclosed biodegradable cyanoacrylate compositions contain a plasticizer, a biocompatible agent, a thickener, Drugs, crosslinkers, dyes or pigments, preservatives, antimicrobial agents, or polymerization initiators or accelerators The disclosed biodegradable cyanoacrylate compositions are sterile, biodegradable, The composition may include a reactive cyanoacrylate composition.
[0123] The disclosed biodegradable cyanoacrylate compositions are components of medical devices. The biodegradable cyanoacrylate composition may include a biodegradable cyanoacrylate composition contained within a container.
[0124] One or more of the biodegradable cyanoacrylate compositions disclosed herein The kit includes a sterile, biodegradable cyanoacrylate composition. The composition may comprise This means that it is sterilized.
[0125] The disclosed biodegradable cyanoacrylate compositions include a) at least one cyanoacrylate. Cyanoacrylate component containing acrylate, and cyanoacrylate is 90wt% or more. a rate component; b) a stabilizer component in the range of 500 ppm to 1500 ppm; and c) and a polymerization inhibitor component in the range of 4000 to 7000 ppm.
[0126] The disclosed biodegradable cyanoacrylate compositions include a) at least one cyanoacrylate. Cyanoacrylate component containing acrylate, and cyanoacrylate is 90wt% or more. a rate component; b) a stabilizer component in the range of 500 ppm to 1500 ppm; and c) and a polymerization inhibitor component in the range of 4000 to 7000 ppm, wherein the composition , Neutral Red cytotoxicity test ( (measured by ISO 10993-5:2009) and at least Biocompatibility test for genetic toxicity (measured according to ISO 10993-3:2003) The disclosed biodegradable cyanoacrylate composition passes the cytotoxicity test. Failed, sensitization (measured by ISO 10993-10:2010), irritation (measured by ISO 10993-10:2010), vaginal irritation (ISO 109 93-10:2010), heat release (measured by ISO 10993-11:20 10), systemic acute toxicity (measured according to ISO 10993-11:2010) systemic subchronic toxicity (measured by ISO 10993-11:2010) (measured by ISO 10993-3:2003), genotoxicity (measured by ISO 10993-3:2003), Rodent blood micronucleus assay (measured by ISO 10993-3:2003) and Mouse lymphoma mutagenesis (measured by ISO 10993-3:2003) The composition contains a biodegradable cyanoacrylate composition that passes each of the biocompatibility tests in is fine.
[0127] The disclosed methods for occluding one or more ducts in a subject include The method comprises administering a sterile, biodegradable cyanoacrylate composition to or near the site of the occlusion. The biodegradable cyanoacrylate composition polymerizes, causing a temporary polymeric blockage in the conduit. over time, the polymerized material degrades and a cellular occlusion forms at the site. and maintaining the composition at the site such that
[0128] The medical device components include the disclosed biodegradable cyanoacrylate compositions. The component may include a container having a biodegradable cyanoacrylate composition. , or both, may contain components that are sterile.
[0129] definition
[0130] As used herein, the term "conduit" refers to any biological material, whether natural or synthetic. Any pipe, duct, or passageway that carries gases, fluids, or solids in a system It shall be so.
[0131] As used herein, "occlude" refers to the removal of gas, fluid or refers to the partial or complete obstruction of the transport of solids. When used in the context of This results in partial restriction or complete interruption of the transport of gases, liquids or solids. As used herein, "occlusion-initiating material" and "biodegradable cyanoacrylate composition" refer to " are used interchangeably and mean to occlude a conduit by achieving occlusion therein. As used herein, an occlusion-initiating material refers to a composition that is capable of being introduced into a conduit. The initial composition (e.g., a biodegradable cyanoacrylate composition) that is applied or inserted is Upon exposure, the material is transported through the duct through its interaction with the tissue, forming an initial blockage. A material that previously passed through a conduit, such as a body or solid, no longer passes through the conduit in an occluded area. Induce or cause to block or obstruct a duct so that it cannot be The clog that forms in the conduit may contain components of the clog-initiating material, or For example, the occlusion may not include the cells of the subject because the occlusion-initiating material is biodegradable. Alternatively, the occlusion-initiating material may comprise only cellular material. The occlusion may include a biodegradable cyanoacrylate composition. As the composition degrades, the occlusion initiating material / cyanoacrylate remaining at the occlusion site The meaning of the term can be determined from its use in the context. Related compositions, biodegradable cyanoacrylate compositions, occlusive compositions, cyanoacrylates Material, occlusion-initiating material, occlusion-initiating composition and occlusion material are the terms used.
[0132] In the initial stages, liquid biodegradable cyanoacrylates After delivery of the plate composition, occlusion is achieved by the polymerized biodegradable cyanoacrylate composition. Over time, the polymerized biodegradable cyanoacrylate composition may be formed primarily of As the cellular component breaks down or is removed from the delivery site, cellular responses and A blockage is formed due to scar tissue or healing outcomes.
[0133] The biodegradable cyanoacrylate compositions of the present disclosure may be in the form of liquids, semi-solids, gels, solids and the like. The cyanoacrylate material may comprise a combination of the following: The biodegradable cyanoacrylate composition may include a composition that cures in situ at room temperature. The method may further include the step of polymerizing the material in situ, where the polymerization occurs at the site of the conduit. The procedure may be initiated either at or prior to placement at the site.
[0134] As used herein, the nomenclature for compounds, including organic compounds, is generally Names may be given using the IUPAC, IUBMB, or CAS recommendations for nomenclature. If one or more stereochemical features are present, Cahn-Ingo Prelog rules can be used to specify stereochemical priorities, EIZ standards, etc. Once a name has been given, one of skill in the art can identify the compound by systematic reduction of the compound structure using naming conventions. or CHEMDRAW (trademark) (Cambridgesoft Corpora The structure of the compound is generated by either commercial software such as NMR (Sigma-Aldrich Co., Ltd., USA) or can be easily ascertained.
[0135] As used in this specification and the appended claims, the singular forms "a," "an," and "the" refer to the "The" includes plural referents unless the context clearly indicates otherwise. For example, a reference to a "functional group," an "alkyl," or a "residue" refers to two or more such groups. The functional groups include mixtures of alkyl or alkyl residues.
[0136] In this specification and in the concluding claims, references to parts by weight of particular elements or components in the composition Reference is made to that element or component and any other parts in the composition or article for which parts by weight are expressed. It expresses the weight relationship between elements or components. Thus, 2 parts by weight of component X and 5 parts by weight of In the compound containing component Y, X and Y are present in a weight ratio of 2:5, and the additional component is They are present in such ratios whether or not they are contained in the compound.
[0137] Weight percent (wt.%) of a component indicates the amount of that component present, unless specifically stated to the contrary. Based on the total weight of the formulation or composition contained.
[0138] As used herein, when a compound is referred to as a monomer or compound, It is understood that this is not to be construed as one molecule or one compound. For example, Two cyanoacrylate monomers refer to two different cyanoacrylate monomers. , does not refer to two molecules.
[0139] As used herein, the terms "optional" or " "Optionally" means that the event or circumstance described thereafter occurs. that may or may not occur, and that the description is an example of an instance in which the event or circumstance occurs. This is meant to include cases where it does and does not occur.
[0140] As used herein, the terms "about," "approximately," and "approximately" include is not intended to limit the scope of the invention, unless the quantity or value in question is specified as an exact value or as recited in the claims. It is believed that the value provides results or effects equivalent to those taught herein. This means that the amount, size, formulation, parameters, and other quantities can be and characteristics are not necessarily exact, but approximate and / or greater or smaller, optionally reflecting tolerances, conversion factors, Please be aware of rounding, measurement error, and other factors known to those skilled in the art that would obtain equivalent results or effects. It is understood that in some circumstances, factors such as In such cases, the values provided herein are generally not reasonably determinable. When used in this document, "about" and "approximately" are used unless otherwise indicated or inferred. , are understood to mean ±10% variation of the nominal value indicated. Formulations, parameters or other quantities or characteristics are expressly described as such. "About," "approximately," or "about When "approximately" or "about" is used before a quantitative value, the parameter Unless otherwise specifically stated, it is understood that the specific quantitative value itself is also included.
[0141] As used herein, "harden" refers to the placement of a desired portion of a conduit at a desired site. or the physical, chemical, or physical and chemical, effects of the cyanoacrylate material after insertion. This refers to a change in properties, and as is commonly understood for polymeric materials, "hardening" " means that the composition transforms from a liquid to a solid or semi-solid.
[0142] As used herein, the term "subject" refers to any mammal, fish, bird, reptile, or The mammalian animal may be a vertebrate, such as a mammalian animal or an amphibian. The Act covers humans, non-human primates, horses, pigs, rabbits, dogs, sheep, goats, cattle, rats, and other animals. The term may refer to a specific age or sex of a mammal. Thus, adult and neonatal subjects and fetuses, both male and female, are covered. In some embodiments, the mammalian subject is a human. refers to a subject suffering from a disorder. The term "patient" includes human and veterinary subjects. In some embodiments of the methods described herein, the subject is induced prior to administration of the cyanoacrylate composition. In some embodiments, the patient has been diagnosed with a condition that requires treatment, including occluding the duct. The elephant is diagnosed as requiring administration of the cyanoacrylate composition prior to the administering step. It is being done.
[0143] As used herein, the terms "administering" and "administration" refer to the disclosed The present invention refers to any method of providing a cyanoacrylate composition to a subject.
[0144] As used herein, the terms "comprises," "including," "comprising", "includes", "including "containing," "characterized by," "has," "has "having" or any other variation thereof is intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that includes a list of elements is intended to be The present invention is not necessarily limited to these elements and does not include any aspect not expressly stated or implied in such program. It may include other elements specific to a process, method, article, or device.
[0145] The transitional phrase "consisting of" excludes any element, step, or Inclusion of any material other than those listed, excluding raw materials and, except for impurities normally associated therewith The phrase "consisting of" is used in the claim rather than immediately following the preamble. When it appears in a section of the body, it limits only the elements specified in that section and not any other Elements generally are not excluded from the claims.
[0146] The transitional phrase "consisting essentially of" extends the scope of a claim to the materials or steps defined. and limited to those that do not materially affect the basic and novel characteristics of the claimed invention. A "consisting essentially of" claim is a closed claim written in "consisting of" format. Such claims occupy a compromise between fully open claims drafted in the "including" format. Additives may contain optional additives as defined herein at appropriate levels. Additives and minor impurities are not excluded from a composition by the term "consisting essentially of."
[0147] Any composition, process, structure, or portion of a composition, process or structure is described herein. If the content is described in the specification using open-ended terms such as "including," Unless otherwise stated, the description is intended to be a composition, process, structure, or a This also includes embodiments in which the structure "consists essentially of" or "consists of" a portion of the structure.
[0148] The articles "a" and "an" refer to any composition, process or may be used in connection with various elements and components of the structure. This is for convenience only, The purpose of such a statement is to give a general sense of the composition, process, or structure. "one or at least one" element or component. where a plural is used, the singular article is used unless the specific context makes it clear that a plural is excluded. , also including descriptions of multiple elements or components.
[0149] The term "about" means that amounts, sizes, formulations, parameters, and other quantities and characteristics are strictly stated. Not necessarily exact, but approximately and / or greater than or less than may be small and, if desired, may be used to reflect tolerances, conversion factors, rounding, measurement errors, etc. This means that the differences may be due to factors such as amount, size, etc., and other factors known to those of skill in the art. Any formulations, parameters or other quantities or characteristics are not expressly set forth as such. "about" or "approximately," regardless of whether such information is provided in a manner that is consistent with the principles of the present invention.
[0150] The term "or" as used herein is inclusive, i.e., the phrase "A or B" means "A, B, or both A and B." More specifically, A condition "A or B" is satisfied by one of the following: A is true (or exists) and B is false (or does not exist); A is false (or does not exist), and B is true (or exists); or both A and B are true (or exist) In this specification, exclusive "or" means, for example, "either A or B." " and "either A or B."
[0151] In addition, ranges set forth herein are intended to cover all ranges unless expressly stated otherwise. These endpoints include those that are not known in the art. , a range, one or more preferred ranges or upper and lower preferred limits When given as a list, this includes any upper range limits or preferred values and any ranges. Any range formed from any pair of lower limits or preferred values is treated as if such pairs were separately Whether or not it is disclosed, it should be understood as specifically disclosed. The scope of the invention is not limited to the specific values recited when defining a range.
[0152] As used herein, a material, method, or machine is defined as "known to those skilled in the art" or "conventional." or when described with a synonym or phrase, the term refers to a material, method, or procedure that is conventional at the time of filing of this application. Terms meaning law and machinery are covered by this description. and materials, methods and methods that will be recognized in the art as suitable for similar purposes. This also includes equipment and machinery.
[0153] Unless otherwise stated, all percentages, parts, ratios and similar amounts are by weight. It is justified.
[0154] All patents, patent applications and references included herein are hereby incorporated by reference. The whole is specifically incorporated.
[0155] Of course, the foregoing relates only to preferred embodiments of the present disclosure, and Numerous modifications may be made without departing from the spirit and scope of the disclosure as set forth herein. It is to be understood that modifications may be made therein. <Additional Notes> Item 1 a) a cyanoacrylate component comprising at least one cyanoacrylate, 0 wt% or more of a cyanoacrylate component; b) a stabilizer component in the range of 500 ppm to 1500 ppm; c) a polymerization inhibitor component in the range of 4000 to 7000 ppm; 1. A biodegradable cyanoacrylate composition comprising: Section 2 Item 1. The biodegradable cyanoacrylate composition according to item 1, wherein the cyanoacrylate component comprises at least two cyanoacrylate monomers. Section 3 Cyanoacrylate monomers are methyl cyanoacrylate, ethyl cyanoacrylate, Propyl cyanoacrylate, butyl cyanoacrylate, pentyl cyanoacrylate , Hexyl Cyanoacrylate, Septyl Cyanoacrylate, Octyl Nonyl Cyanoacrylate Noacrylate, Decyl 2-Cyanoacrylate, Allyl Cyanoacrylate, Methoxy Ethyl cyanoacrylate, methoxyisopropyl cyanoacrylate, methoxypropyl Lysyl cyanoacrylate, methoxybutyl cyanoacrylate, methoxypentyl cyanoacrylate Item 3. The biodegradable cyanoacrylate composition according to item 1 or 2, which is a cyanoacrylate, a methacrylate, or a combination thereof. Section 4 The stabilizer component is alkyl sulfide, alkyl sulfate, alkyl sulfonyl, alkyl sulfone, alkyl sulfoxide, alkyl sulfite, sultone, sulfur dioxide, triacid sulfur fluoride, sulfonic acid, lactone, boron trifluoride, acetic acid, or 3-sulfolene, mer Item 4. The biodegradable cyanoacrylate composition of any one of items 1 to 3, comprising a cyclohexyl acrylate, ... Section 5 Item 5. The biodegradable cyanoacrylate composition of item 4, wherein the stabilizer component comprises sulfur dioxide or sulfur trioxide. Section 6 The polymerization inhibitor components are butyl hydroxyanisole (BHA), hydroquinone, and catechol. hindered compounds such as hydroquinone monomethyl ether and butyl hydroxyanisole; Phenol; 4-ethoxyphenol; Butylated hydroxytoluene (BHT, 2,6- Di-tert-butyl phenol), 4-methoxyphenol (MP); 3-Methoxyphenol 2-tert-butyl-4-methoxyphenol; or 2,2-methyl ethylene-bis-(4-methyl-6-tert-butylphenol), or combinations thereof The biodegradable cyanoacrylate composition of claim 1 , comprising: Section 7 Item 7. The biodegradable cyanoacrylate composition according to item 6, wherein the polymerization inhibitor component comprises BHA or BHT. Section 8 Hydrogen sulfide, carbonic acid, triacetylmethane, acetic acid, benzoic acid, dinitrophenol, formic acid, Nitrous acid, hydrochloric acid, hydrobromic acid, hydrofluoric acid, chloroacetic acid, phosphoric acid, dichloroacetic acid, trichloroacetic acid Perfluoroacetic acid, trinitrophenol, trifluoroacetic acid, sulfuric acid, perchloric acid, toluene sulfuric acid 8. The biodegradable cyanoacrylate composition of any one of claims 1 to 7, further comprising a sulfonic acid or a fluorosulfonic acid, or a combination thereof. Section 9 Plasticizers, biocompatible agents, thickeners, medicines, crosslinking agents, dyes or pigments, preservatives, antimicrobial agents, Item 9. The biodegradable cyanoacrylate composition according to any one of items 1 to 8, further comprising a polymerization initiator or accelerator. Section 10 Item 10. The biodegradable cyanoacrylate composition according to any one of items 1 to 9, which is sterile. Section 11 Item 11. The biodegradable cyanoacrylate composition of any one of items 1 to 10, contained within a container that is a component of a medical device. Section 12 Item 12. A kit comprising the biodegradable cyanoacrylate composition according to any one of items 1 to 11. Section 13 Item 13. The kit according to item 12, wherein the biodegradable cyanoacrylate composition is sterile. Section 14 a) a cyanoacrylate component comprising at least one cyanoacrylate, 0 wt% or more of a cyanoacrylate component; b) a stabilizer component in the range of 500 ppm to 1500 ppm; c) a polymerization inhibitor component in the range of 4000 to 7000 ppm; 1. A biodegradable cyanoacrylate composition comprising: Section 15 a) a cyanoacrylate component comprising at least one cyanoacrylate, 0 wt% or more of a cyanoacrylate component; b) a stabilizer component in the range of 500 ppm to 1500 ppm; c) a polymerization inhibitor component in the range of 4000 to 7000 ppm; Including, Neutral Red Cytotoxicity Test (measured by ISO 10993-5:2009) and at least genotoxicity (according to ISO 10993-3:2003). Pass one or more biocompatibility tests, including those for Biodegradable cyanoacrylate compositions. Section 16 Item 16. The biodegradable cyanoacrylate composition of item 15, wherein the cyanoacrylate component comprises at least two cyanoacrylate monomers. Section 17 Cyanoacrylate monomers are methyl cyanoacrylate, ethyl cyanoacrylate, Propyl cyanoacrylate, butyl cyanoacrylate, pentyl cyanoacrylate , Hexyl Cyanoacrylate, Septyl Cyanoacrylate, Octyl Nonyl Cyanoacrylate Noacrylate, Decyl 2-Cyanoacrylate, Allyl Cyanoacrylate, Methoxy Ethyl cyanoacrylate, methoxyisopropyl cyanoacrylate, methoxypropyl Lysyl cyanoacrylate, methoxybutyl cyanoacrylate, methoxypentyl cyanoacrylate Item 17. The biodegradable cyanoacrylate composition according to item 15 or 16, which is a cyanoacrylate, a methacrylate, a methacrylate, or a combination thereof. Section 18 The stabilizer component is alkyl sulfide, alkyl sulfate, alkyl sulfonyl, alkyl sulfone, alkyl sulfoxide, alkyl sulfite, sultone, sulfur dioxide, triacid sulfur fluoride, sulfonic acid, lactone, boron trifluoride, acetic acid, or 3-sulfolene, mer 18. The biodegradable cyanoacrylate composition of any one of paragraphs 15 to 17, comprising a cyclohexyl acrylate, ... Section 19 Item 19. The biodegradable cyanoacrylate composition of item 18, wherein the stabilizer component comprises sulfur dioxide or sulfur trioxide. Section 20 The polymerization inhibitor components are butyl hydroxyanisole (BHA), hydroquinone, and catechol. hindered compounds such as hydroquinone monomethyl ether and butyl hydroxyanisole; Phenol; 4-ethoxyphenol; Butylated hydroxytoluene (BHT, 2,6- Di-tert-butyl phenol), 4-methoxyphenol (MP); 3-Methoxyphenol 2-tert-butyl-4-methoxyphenol; or 2,2-methyl ethylene-bis-(4-methyl-6-tert-butylphenol), or combinations thereof 20. The biodegradable cyanoacrylate composition according to any one of items 15 to 19, comprising: Section 21 Item 21. The biodegradable cyanoacrylate composition according to item 20, wherein the polymerization inhibitor component comprises BHA or BHT. Section 22 Hydrogen sulfide, carbonic acid, triacetylmethane, acetic acid, benzoic acid, dinitrophenol, formic acid, Nitrous acid, hydrochloric acid, hydrobromic acid, hydrofluoric acid, chloroacetic acid, phosphoric acid, dichloroacetic acid, trichloroacetic acid Perfluoroacetic acid, trinitrophenol, trifluoroacetic acid, sulfuric acid, perchloric acid, toluene sulfuric acid 22. The biodegradable cyanoacrylate composition of any one of claims 15 to 21, further comprising a sulfonic acid or a fluorosulfonic acid, or a combination thereof. Section 23 Plasticizers, biocompatible agents, thickeners, medicines, crosslinking agents, dyes or pigments, preservatives, antimicrobial agents, 23. The biodegradable cyanoacrylate composition according to any one of claims 15 to 22, further comprising a polymerization initiator or accelerator. Section 24 24. The biodegradable cyanoacrylate composition according to any one of items 15 to 23, which is sterile. Section 25 25. The biodegradable cyanoacrylate composition of any one of paragraphs 15 to 24, contained within a container that is a component of a medical device. Section 26 Item 26. A kit comprising the biodegradable cyanoacrylate composition according to any one of items 15 to 25. Section 27 Item 27. The kit of item 26, wherein the biodegradable cyanoacrylate composition is sterile. Section 28 A method for occluding one or more ducts in a subject, comprising administering a sterile biodegradable cyanoacrylate composition according to any one of paragraphs 1 to 26 to or near the site of occlusion. and administering the biodegradable cyanoacrylate composition to the conduit, the biodegradable cyanoacrylate composition polymerizing and forming a biodegradable cyanoacrylate composition in the conduit. provides a temporary polymerized occlusion, and over time, the polymerized material degrades and the cellular occlusion is eliminated. and maintaining the composition at the site so that it forms at the site. ,method. Section 29 26. A component of a medical device comprising a container containing the biodegradable cyanoacrylate composition according to any one of claims 1 to 25. Section 30 30. The component of paragraph 29, wherein the container, the biodegradable cyanoacrylate composition, or both, are sterile.
[0156] The present disclosure is further illustrated by the examples contained herein, which are to be construed as being within the scope of the present disclosure. However, the present disclosure is not intended to be limiting in any way. Without departing from the scope of the appended claims, the description herein may be read as follows: Various other embodiments, modifications, and equivalents thereof, which may subsequently be suggested to those skilled in the art, must be resorted to. It should be clearly understood that this may not be possible. EXAMPLES
[0157] Working Example
[0158] Example 1 Biodegradable Cyanoacrylate Compositions in a 52-Week Rabbit Tubal Implant Study
[0159] The study examined the efficacy of the biodegradable cyanoacrylate compositions disclosed herein in surgical procedures. The biodegradable cyanoacrylate composition includes, for example, all of the components 0.42 g of methoxypropyl cyanoacrylate to form the cyanoacrylate component 0.18 g of methoxyisopropyl cyanoacrylate (MPCA) and 0.18 g of methoxyisopropyl cyanoacrylate (MI PCA), stabilizer component, 0.0004g SO 2 0.003g of BHA (butyl hydrochloride) A polymerisation inhibitor is premixed with cyanoacrylate, The composition was prepared by forming a sufficient amount of a biodegradable cyanoacrylate composition. We developed a new PICC-NATE catheter and screened rabbits using it. The drug is delivered to the fallopian tube to mimic human use and polymerize in situ in the fallopian tube in vivo. The presence of biodegradable cyanoacrylate compositions in the fallopian tube and the progression of their degradation were examined. The study assessed the effects of a range of cyanoacrylate compositions on animals. To assess the extent and nature of tubal obstruction created by cyanoacrylate compositions The local tissue reaction during the presence and degradation of the component was evaluated over time to determine the shear To assess the safety of the non-acrylate composition and to determine the degradation profile of the test articles over time. The objectives of this study were to thoroughly characterize the compound as well as to provide limited systemic toxicity data.
[0160] Thirty-seven female New Zealand White rabbits were treated with a biodegradable cyanoacrylate composition. Four were euthanized within a few days of treatment. Seven sham-treated animals and Twenty-seven treated animals underwent pathology analysis at the following time points: 2 and 4 weeks, 3 months, 6 months, and 12 months. The period was 12 months.
[0161] There were no systemic toxic effects. Other than local cellular reactions, there were no adverse local tissue effects. Complete tubal occlusion was present in 60% of the tubes at 3 and 6 months. The materials were almost completely decomposed within 3 to 6 months, and almost no material remained after 12 months. Research has shown that cyanoacrylate compositions elicit a foreign body response in the fallopian tubes, which leads to scar tissue. Administration to the oviduct of rabbits was shown to cause oviduct occlusion. No other symptoms were observed to develop, and inflammation, necrosis, and other symptoms were mainly limited to the 28-day time point. These changes produced local treatment-related effects, including inflammatory and healing responses. were observed in the majority of cases, but not at 90 or 180 days.
[0162] Example 2 Test for Cytotoxicity ISO 10993-5
[0163] Test Articles of Polymerized Biodegradable Cyanoacrylate Composition Used in Example 1 Mammalian cell cultures (mouse fibroblast L929 cells) in response to exposure to extracts (test articles) of The potential biological reactivity of the test articles was determined in a minimum of 10% fetal bovine serum. in essential medium (MEM) (referred to as complete MEM) at 37±1°C for 24±2 hours Negative and positive controls were prepared similarly. Maintenance medium of 929 cells was diluted with 100% (undiluted) extract of the test article and the control article in sextuplicate. The cells were then replaced and incubated at 37±1° C. for 24 to 26 hours. Cell viability after exposure to the vital dye, Neutral Red (NR), was assessed. The dye was added to cells to be actively incorporated into viable cells. The number of viable cells correlates with the color intensity, determined photometrically after extraction. After the exposure time, the cells were washed with phosphate-buffered saline (PBS) and incubated in sterile Neutral Red Culture medium (50 micrograms / mL in MEM without Phenol Red) was added to each test well. and the cells were incubated in an incubator at 37±1°C for 3±0.2 hours. The cells were then washed with PBS and incubated with 150 microliters of ethanol / mL. Acetic acid solution was added to each well to extract NR. The optical density (OD) of each well was then measured. was measured.
[0164] The negative control was HDPE (negative control plastic) and the positive control was natural rubber. An untreated control, no added plastic or material, was also used.
[0165] The survival percentage of cells exposed to 100% (undiluted) test article extract was 17%. The survival percentages of cells exposed to the negative and positive control articles were: The assay was validated by both greater and less than 70% of the protocol. Based on the standard and the ISO 10993-5 guidelines, the test article meets the requirements of the test. It is considered to have a cytotoxic effect.
[0166] In vitro cytotoxicity studies have been performed to assess leaching from polymerized biodegradable cyanoacrylate compositions. demonstrated that the solution produced a significant decrease in cell viability. This was accompanied by local implantation site reactivity observed in the cutaneous tissue but not in the subcutaneous tissue. and the polymer extract was not irritating after intradermal injection or application to the vagina of rabbits. Local implant site reactivity was assessed using the FDA-approved tissue adhesive Histoacryl (butyl silyl). The response was virtually identical when compared to the response generated by the acrylate control implants. The observed local irritation and cytotoxicity were due to the cyanoacrylates incorporated into the polymer. This is likely due to acrylates.
[0167] Example 3 Pre-hysterectomy testing
[0168] Implantation of biodegradable cyanoacrylate compositions in human subjects is consistent with all prior human experiments. The biodegradable cyanoacrylate composition was prepared according to the method described herein. by providing at least the horn of the fallopian tube using the device disclosed in Human females undergoing a hysterectomy procedure were pretreated with the following biodegradable cyanoacrylates: An acrylate composition was used.
[0169] Biodegradable cyanoacrylate composition 100wt% MCPA (cyanoacrylate component ), BHA5000ppm (polymerization inhibitor component) and 2260SO 2 (Stabilizer component).
[0170] Biodegradable Cyanoacrylate Composition 50wt% MCPA and 50wt% MIPC A (cyanoacrylate component), BHA5000ppm (polymerization inhibitor component) and 22 60SO 2 (Stabilizer component).
[0171] Biodegradable cyanoacrylate composition 70wt% MCPA and 30wt% MIPC A (cyanoacrylate component), BHA5000ppm (polymerization inhibitor component) and 22 60SO 2 (Stabilizer component).
[0172] A total abdominal hysterectomy procedure with bilateral salpingectomy was performed using a biodegradable cyanoacrylate composition. The fallopian tubes were examined microscopically and histopathologically either 28 or 29 days after administration. Some subjects showed the presence of polymerized composition, others showed local inflammatory and healing responses. A complete healing response was observed in the blocked fallopian tube. Responses to cyanoacrylate compositions ranged from little to no material, to slight to significant. The findings ranged from a clear inflammatory cell pattern to luminal obstruction due to an inflammatory healing response. In some cases, inflammatory reactive cells were also present. In one patient, the fallopian tube was 70-90% of the length of 2 mm. Stenosis, followed by 100% occlusion of 2 mm in the interstitial segment, The isthmus segment was 2 mm long and had a complete stenosis of 18 mm. Lumenal obstruction progressed to 100%. Complete luminal obstruction was noted in three fallopian tubes, the other two The inflammatory response generally correlated with the presence of polymerized composition. Ta.
Claims
1. a) a cyanoacrylate component consisting of methoxyisopropyl cyanoacrylate and methoxypropyl cyanoacrylate, the cyanoacrylate component being 80 wt % or more, and the weight ratio of the methoxyisopropyl cyanoacrylate to the methoxypropyl cyanoacrylate being 50:50, 30:70, or 70:30; b) a stabilizer component in the range of 500 ppm to 1500 ppm; c) a polymerization inhibitor component in the range of 4000 ppm to 7000 ppm; Including, the stabilizer component is an alkyl sulfide, an alkyl sulfate, an alkyl sulfonyl, an alkyl sulfone, an alkyl sulfoxide, an alkyl sulfite, a sultone, a sulfur dioxide, a sulfur trioxide, a sulfonic acid, a lactone, boron trifluoride, acetic acid, 3-sulfolene, or a mercaptan, or a combination thereof; The polymerization inhibitor component is butylated hydroxyanisole (BHA); hydroquinone; catechol; hydroquinone monomethyl ether and hindered phenols; 4-ethoxyphenol; butylated hydroxytoluene (BHT); 2,6-di-tert-butylbutylphenol; 4-methoxyphenol (MP); 3-methoxyphenol; 2-tert-butyl-4-methoxyphenol; or 2,2-methylene-bis-(4-methyl-6-tert-butylphenol), or a combination thereof. Biodegradable cyanoacrylate compositions.
2. 10. The biodegradable cyanoacrylate composition of claim 1, wherein the stabilizer component comprises sulfur dioxide or sulfur trioxide.
3. 3. The biodegradable cyanoacrylate composition of claim 1 or 2, wherein the polymerization inhibitor component comprises BHA or BHT.
4. 4. The biodegradable cyanoacrylate composition of any one of claims 1 to 3, further comprising hydrogen sulfide, carbonic acid, triacetylmethane, acetic acid, benzoic acid, dinitrophenol, formic acid, nitrous acid, hydrochloric acid, hydrobromic acid, hydrofluoric acid, chloroacetic acid, phosphoric acid, dichloroacetic acid, trichloroacetic acid, trinitrophenol, trifluoroacetic acid, sulfuric acid, perchloric acid, toluenesulfonic acid, or fluorosulfonic acid, or a combination thereof.
5. 5. The biodegradable cyanoacrylate composition of claim 1, further comprising a plasticizer, a biocompatible agent, a thickener, a pharmaceutical, a crosslinking agent, a dye or pigment, a preservative, an antimicrobial agent, or a polymerization initiator or accelerator.
6. The biodegradable cyanoacrylate composition of claim 1 which is sterile.
7. 7. The biodegradable cyanoacrylate composition of claim 1 contained within a container that is a component of a medical device.
8. A biodegradable cyanoacrylate composition described in any one of claims 1 to 7, wherein the cyanoacrylate component is 90 wt % or more.
9. The biodegradable cyanoacrylate composition of claim 8, wherein the cyanoacrylate component is 98 wt % or more.
10. A biodegradable cyanoacrylate composition according to any one of claims 1 to 9 for occluding a duct in the body.
11. A kit comprising the biodegradable cyanoacrylate composition of any one of claims 1 to 10.
12. The kit of claim 11 , wherein the biodegradable cyanoacrylate composition is sterile.
13. 1. A sterile biodegradable cyanoacrylate composition for use in a method for occluding one or more ducts in a subject, comprising: The sterile biodegradable cyanoacrylate composition is a biodegradable cyanoacrylate composition according to any one of claims 1 to 10, The method includes administering the sterile biodegradable cyanoacrylate composition to or near a site of an obstruction; and maintaining the composition at the site such that the biodegradable cyanoacrylate composition polymerizes and provides a temporary polymeric obstruction in the conduit, and over time, the temporary polymeric obstruction degrades and a cellular obstruction forms at the site. A sterile, biodegradable cyanoacrylate composition.
14. A component of a medical device comprising a container containing the biodegradable cyanoacrylate composition of any one of claims 1 to 10.
15. The component of claim 14 , wherein the container, the biodegradable cyanoacrylate composition, or both, are sterile.
Citation Information
Patent Citations
JP1974016102A
Sterilized cyano acrylate adhesive composition and production thereof
JP1995252455A
Alfa-cyanoacrylate-including photosetting resin composition
JP2002322220A
Electron beam sterilization method for liquid adhesive composition
JP2002503522A
Polymerizable composition and method for using it
JP2009120851A
Cited By
Methods and compositions comprising biodegradable cyanoacrylates
US12606719B2
